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Dissecting the non-canonical functions of p53 through novel target identification 
and p53 acetylation 
Shang-Jui Wang 
 
It is well established that the p53 tumor suppressor plays a crucial role in controlling 
cell proliferation and apoptosis upon various types of stress. There is increasing 
evidence showing that p53 is also critically involved in various non-canonical pathways, 
including metabolism, autophagy, senescence and aging. Through a ChIP-on-chip 
screen, we identified a novel p53 metabolic target, pantothenate kinase-1 (PANK1). 
PanK1 catalyzes the rate-limiting step for CoA synthesis, and therefore, controls 
intracellular CoA content; Pank1 knockout mice exhibit defect in -oxidation and 
gluconeogenesis in the liver after starvation due to insufficient CoA levels. We 
demonstrated that PANK1 gene is a direct transcriptional target of p53. Although DNA 
damage-induced p53 upregulates PanK1 expression, depletion of PanK1 expression 
does not affect p53-dependent growth arrest or apoptosis. Interestingly, upon glucose 
starvation, PanK1 expression is significantly reduced in HCT116 p53 (-/-) but not in 
HCT116 p53 (+/+) cells, suggesting that p53 is required to maintain PanK1 expression 
 
under metabolic stress conditions. Moreover, by using p53-mutant mice, we observed 
that PanK activity and CoA levels are lower in livers of p53-null mice than that of 
wild-type mice upon starvation. Similar to the case in Pank1 knockout mice, -oxidation 
and gluconeogenesis are impaired in p53-null mice. Together, our findings show that p53 
is critical in regulating energy homeostasis through transcriptional control of PANK1. 
Our study on PANK1 led us to the question of how p53 can differentially regulate a 
diverse array of downstream targets in a context-dependent manner. Studies have 
shown that p53 acetylation at K120 and K164 lysine residues contribute to p53-mediated 
apoptosis and growth arrest functions, which was further supported by the 3KR mouse 
model (K117/161/162R) that mirrors the K120/164R mutations in human p53. These 
studies also suggest that a potentially large number of p53 targets can still be regulated 
by p53 in the absence of K120/164 acetylation (K117/161/162R in mouse). To 
investigate whether additional modifications of p53 can further contribute to 
promoter-specific transactivation, we conducted a screen using mass spectrometry and 
identified a novel acetylation site at K101. Our data demonstrated that K101 in human 
p53, as well as the homologous K98 lysine residue in mouse p53, can be acetylated by 
acetyltransferase CBP. Acetylation at this novel site does not contribute to p53 stability 
or DNA-binding capabilities. Ablation of K98 acetylation in mouse p53 alone does not 
 
affect the transcriptional activity of p53. However, simultaneous loss of K98 acetylation 
with the previously characterized K117/161/162 acetylations (4KR98 p53) significantly 
abrogates p53-mediated activation of TIGAR and MDM2 genes. 
The 3KR mouse model, although cannot elicit canonical p53-mediated apoptotic 
and cell cycle arrest responses, still retains the ability to suppress tumor formation. We, 
therefore, investigated whether other non-canonical targets of p53 could potentially 
mediate tumor suppression. By RNA-seq profiling of gene expression in cells expressing 
3KR p53, we identified TNFRSF14 (tumor necrosis factor receptor superfamily, member 
14) as a novel p53 target. The TNFRSF14 receptor has been shown to be frequently 
mutated in follicular lymphoma and diffuse large B cell lymphoma, and stimulation by its 
ligand LIGHT leads to cell death in many cancer cells. We report that TNFRSF14 is a 
novel p53 target that can be activated by 3KR p53. Interestingly, transactivation of 
TNFRSF14 is defective by 4KR98 p53. Furthermore, LIGHT ligand stimulates cell death 
in TNFRSF14-expressing cells and cells expressing 3KR p53, but not those expressing 
4KR98 p53. 
Altogether, our findings in these studies underscore the extensive scope of p53 
functions and provide new insights into the versatility of non-canonical pathways. Not 
only does p53 mediate tumor suppression through both canonical and non-canonical 
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1.1. p53 tumor suppressor 
 The p53 protein is a tumor suppressor that is found to be mutated in more than 50% 
of sporadic tumors, and is one of the most important tumor suppressors that prevents 
malignant transformation in mammalian cells [1-4]. The primary functions of p53 are 
mediated by its role as a transcription factor that binds sequence-specific DNA on its 
target promoters, and subsequently activates or represses target gene expression [5]. 
The importance of p53 transcriptional activity is highlighted by the observation that most 
tumor-prone p53 mutations occur within the central core domain responsible for DNA 
binding [2]. Individuals with Li-Fraumeni syndromes carry germline p53 mutations that 
confer high familial risk of cancer [2,6]. Deletion of p53 does not cause developmental 
defects, but results in a significantly shortened latency of cancer onset [7]. 
 The p53 protein forms a homotetramer that recognizes p53 response element at 
target promoter containing two decamers with the following consensus sequence: 
PuPuPuC(A/T)|(A/T)GPyPyPy (Pu – purine; Py – pyrimidine) [8]. Each p53 subunit 
contains an N-terminal transactivation domain, a DNA-binding core domain, a 
tetramerization domain, and a C-terminal regulatory domain. The core domain binds to 
the consensus p53 sequence on the target promoter, while the transactivation domain 
recruits transcriptional machinery and co-activators to activate transcription. The 
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tetramerization domain allows four p53 subunits to come together as a tetramer, and the 
C-terminal domain is heavily regulated by post-translational modifications, which in turn 
modulate p53 transcriptional activity [9-12]. 
Classically, p53 functions as a master regulator that controls the expression of 
downstream targets that are responsible for cell fate control. In response to cellular 
stresses such as hypoxia, genotoxic and oncogenic stress, p53 activity and level is 
increased to induce growth arrest, senescence or apoptosis [13,14]. Under mild stress, 
p53 induces cell cycle arrest to allow cells to repair damage or recover from stress 
before resuming normal replication. Alternatively, upon severe stress that causes 
irreparable damage, p53 either triggers senescence, an irreversible cell cycle arrest, or 
activates a number of pro-apoptotic genes to terminate the cell, and thus, preventing 
potential oncogenic mutations to prevail [3]. 
Growth arrest function of p53 is predominantly carried out by the upregulation of p21 
(WAF1) expression, as well as that of GADD45 and 14-3-3 [15-17]. The p21 protein 
binds directly to and inhibits the activity of several cyclin-dependent kinase complexes 
(CDK1/2/4/6) that promotes cell cycle progression, and thus, halts cell cycle at G1 and S 
phases [15]. On the other hand, GADD45 and 14-3-3 contribute to G2 arrest through 
inhibition of cyclin B/cdc2 [16,17]. 
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Mediators of p53-dependent apoptosis include members of the Bcl-2 family of 
proteins - PUMA, BAX, and NOXA. The p53 upregulated modulator of apoptosis (PUMA) 
protein interacts and sequesters anti-apoptotic Bcl-2 family members, allowing 
pro-apoptotic proteins to initiate apoptosis [18,19]. One such protein is the 
Bcl-2-associated X (BAX) protein, which upon activation forms oligomeric pores on the 
outer membrane of mitochondria that result in the release of cytochrome C, leading to 
caspase-dependent apoptosis [20,21]. Similar to PUMA, NOXA undergoes BH3 
motif-dependent localization to the mitochondria and interacts with anti-apoptotic Bcl-2 
family members that result in subsequent caspase activation [22,23]. 
 
1.2. Non-canonical functions of p53 
Recently, the roles of p53 have expanded beyond the canonical functions of 
apoptosis and cell growth arrest, and now include cellular processes such as metabolism, 
autophagy, senescence and aging [3,4]. While apoptotic and growth arrest functions of 
p53 has long been thought to mediate p53-dependent tumor suppression, emerging 
evidence suggest that non-canonical functions of p53 may also play critical roles in this 















Figure 1.1. Tumor suppression by p53 is mediated through multiple functional 
branches. Aside from the canonical apoptotic and growth arrest functions, p53 can 
confer tumor suppression via regulation on senescence, autophagy, and metabolism. 
Most of these functions are carried out by downstream targets that are transcriptionally 
regulated by p53 (some examples shown in the blue boxes). However, p53 also 
assumes cytoplasmic roles in regulating autophagy and cell death that is independent of 





1.2.1. Metabolism and oxidative balance 
Not until recent discoveries that link p53 to cellular metabolism, tumor suppressing 
functions of p53 have long been attributed to its ability to regulate cell cycle through 
apoptosis, growth arrest, and senescence [24,25]. However, as tumorigenesis is 
increasingly viewed as a process that involves complex metabolic perturbations, the role 
of p53 in suppressing tumor formation is also increasingly seen as a metabolic one 
(Figure 1.2). 
Cancer cells acquire numerous metabolic alterations to enable rapid growth and 
proliferation, including aerobic glycolysis (the Warburg effect) and enhanced 
biosynthesis of macromolecules [26,27]. Aerobic glycolysis allows cancer cells to rapidly 
generate ATP at the cost of efficiency while providing intermediates for de novo 
synthesis and oxidative balance. Processes such as aerobic glycolysis and 
glutaminolysis promote biosynthesis of protein, lipids and nucleic acids, which promote 
cancer cells to grow and proliferate more rapidly, and in some cases, confer survival 
advantages of tumor cells [28,29]. Reversing the Warburg effect compromises 
tumorigenicity and survival of cancer cells, while inhibiting glutaminolysis hinders 
oncogenic transformation of normal cells [30-32]. 











Figure 1.2. p53 exerts a diverse array of metabolic functions. A broad spectrum of 
metabolic targets are regulated by p53, leading to various functional outcomes in tumor 
and normal physiology. Genes in blue boxes are previously-identified p53 targets, while 
those in green boxes are most recently discovered. Dashed line in the GLS2 axis 
illustrates the potential of this target in enhancing tumor survival based on its function. 
Abbr. OXPHOS, oxidative phosphorylation; S1P, sphingosine-1-phosphate; FAO, fatty 
acid oxidation; CoA, coenzyme A. 
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alterations observed in tumor cells, which include inhibition of aerobic glycolysis, 
upregulation of mitochondrial OXPHOS, and promotion of fatty acid oxidation [24]. 
Additionally, several of these targets aim to increase antioxidant production and to lower 
intracellular reactive oxygen species (ROS), a protective mechanism to thwart 
ROS-induced DNA damage and subsequent malignant transformation [33,34]. As a 
tumor suppressor, p53 functions to bolster mitochondrial oxidative phosphorylation 
(through activating targets such as SCO2/GLS2/Parkin) and inhibits aerobic glycolysis 
(via expression of TIGAR and repression of GLUT1/3/4), which antagonize the 
predominant utilization of glycolysis in cancer cells [35-41]. 
Synthesis of cytochrome c oxidase (SCO2) regulates the cytochrome C oxidase 
complex of the electron transport chain and increases mitochondrial respiration [35]. 
Depletion of p53 resulted in the decrease in SCO2 expression, which led to a decrease 
in mitochondrial respiration and oxygen consumption. One isoform of glutaminase 
(GLS2), also a p53 target, converts glutamine to glutamate, which can either enter the 
TCA cycle or be used as a substrate for glutathione synthesis [36,37]. Functionally, 
expression of GLS2 contributes to mitochondrial respiration through increasing 
α-ketogluterate flux into the TCA cycle, while also lowering ROS levels through 
increasing antioxidant glutathione production. Expression of Parkin also promotes 
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mitochondrial oxidative phosphorylation by increasing the cellular level of acetyl-CoA 
through the upregulation of pyruvate dehydrogenase E1α1 [38]. 
Regulation on glycolysis by p53 include TP53-induced glycolysis and apoptosis 
regulator (TIGAR), which is an enzyme that converts fructose-2,6-bisphosphate to 
fructose-6-phosphate [39]. This conversion relieves the positive allosteric regulation on 
glycolysis, and thereby, inhibits glycolysis and shunts glycolytic intermediates into the 
pentose phosphate pathway for NADPH production and glutathione recycling [39]. 
Consequently, TIGAR expression reduces the rate of glucose breakdown and decreases 
intracellular ROS. On the other hand, p53 also transcriptionally represses the expression 
of glucose transporters GLUT1/3/4, and therefore, prevents the uptake of glucose and 
reduces glycolytic rate [40,41]. 
More recently, p53 has been implicated in lipid metabolism as well. Indeed, many 
tumor cells also exhibit high rates of de novo lipid synthesis, and several p53 metabolic 
targets may possibly counteract such phenomenon via promoting fatty acid oxidation. 
Jiang et al. identified two repression targets of p53, malic enzyme isoforms 1 and 2 (ME1 
and ME2) [42]. ME1 and ME2 catalyze the oxidative decarboxylation of malate in the 
TCA cycle to pyruvate and NADH/NADPH. Increase in lipid production was observed in 
p53-deficient cells due to abundance of NADPH, while silencing of malic enzymes 
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decreases glutamine consumption and glutaminolysis. Interestingly, reduction of ME1/2 
expressions can reciprocally activate p53, which led to increased cellular senescence 
and decreased tumorigenicity of cancer cells, likely through metabolic perturbations that 
are unfavorable for cancerous growth [42]. 
In another study, Heffernan-Stroud et al. reported that p53 negatively regulate 
sphingosine kinase 1 (SK1) via a proteolytic pathway [43]. SK1 is a key enzyme in 
sphingolipid metabolism that maintains the homeostatic balance of ceramide and 
sphingosine. Specifically, p53-null mice exhibit increase in SK1 levels that leads to an 
increase in the pro-growth sphingolipid sphingosine-1-phosphate and a decrease in the 
anti-growth sphingolipid ceramide [43]. Interestingly, loss of SK1 promotes tumor cell 
senescence in the thymus of p53-null mice through the elevation of p21 and p16 
expressions. Ablation of SK1 reduces tumor formation in p53-null and p53 heterozygous 
mice, indicating a novel mechanism of p53 tumor suppressing function through 
sphingolipid regulation [43]. 
Aside from its function in tumor suppression, p53 also regulate metabolic targets 
that serve to maintain homeostasis in normal cells and tissues. A recently identified p53 
target, Lipin1 is a nuclear transcriptional co-activator that regulates the expression of 
genes involved in fatty acid oxidation through peroxisome proliferator-activated receptor 
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alpha (PPAR α) [44]. Under conditions of low glucose, cells upregulate Lipin1 expression 
through ROS-induced p53 activity and increase fatty acid oxidation to utilize fatty acid as 
an alternative source of energy [44]. 
In summary, p53 metabolic targets are involved in increasing mitochondrial 
respiration, decreasing glycolysis, promoting antioxidant defense and regulating lipid 
metabolism, all of which could contribute to p53-mediated tumor suppression. Moreover, 
metabolic functions of p53 further extend outside of tumor suppression to regulate 
cellular homeostasis in normal physiology, underscoring the multitude of p53 regulation. 
 
1.2.2. Autophagy 
Autophagy is a cellular process in which proteins with long half-life and damaged 
organelles are targeted to lysosome for degradation and recycling. It is a critical pathway 
for eliminating unwanted cellular components and allowing cells to adapt to nutrient 
deprivation and hypoxic stress. Recent evidence also linked p53 function to autophagy. 
While nuclear p53 promotes autophagy through the transcription of pro-autophagic 
genes, cytoplasmic p53 appears to inhibit autophagy via transcription-independent 
mechanisms. 
DRAM (damage-regulated autophagy modulator) is a lysosomal transmembrane 
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protein regulated by p53 [45]. Functioning at the crossroad between autophagy and cell 
death, DRAM induces autophagy downstream of p53, while also contributes to 
p53-mediated apoptosis. Furthermore, DRAM was found to be down-regulated in certain 
primary tumors with retention of wild-type p53, suggesting that autophagic regulation by 
p53 can also contribute to tumor suppression [45].  
Several other p53 targets can also promote autophagy via inhibition of the mTOR 
(mammalian target of rapamycin) axis, a negative regulatory pathway of autophagy. 
AMP-activated protein kinase (AMPK) is a sensor of cellular energy levels that can 
promote autophagy by phosphorylating tuberous sclerosis complex (TSC) proteins TSC1 
and TSC2, and thereby, inhibits mTOR activity [46]. Interestingly, both the β1 and β2 
subunits of AMPK and TSC2 are transcriptional targets of p53, and activation of these 
targets can induce autophagy [47]. 
Mechanism of how cytoplasmic p53 can inhibit autophagy is still poorly 
characterized. However, several evidence demonstrated that either in the absence of 
nuclear p53 (through enucleation) or in the presence of cytoplasmic-localized mutant 
p53, inhibition of autophagy persists [48,49]. Furthermore, the degree of autophagic 
inhibition depended on the ratio of cytoplasmic-to-nuclear p53 levels, with higher 
cytoplasmic p53 fraction resulting in greater inhibitory effects [49]. 
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1.2.3. Senescence and aging 
While cell cycle arrest is transient and reversible, cellular senescence is a 
permanent aging-related biological process in which cells cease to divide. In normal 
aging, telomere shortening is the primary initiating event for senescence and aging [50]. 
On the other hand, persistent oncogenic signaling also triggers a senescence response, 
also known as oncogene-induced senescence [51]. In either case, genetic instability or 
DNA damage transpires, and p53 is activated to promote senescence. Studies showed 
that p21 and plasminogen activator inhibitor-1 (PAI-1) are key effectors of p53-mediated 
senescence [52-54]. More recently, a novel p53 target E2F7 can also mediate 
p53-dependent senescence. E2F7 is a transcription factor that represses many genes 
essential for mitosis, including E2F1, cyclin A, cyclin B, and cdc2/cdk1 [55,56]. The E2F7 
transcription factor was shown to be upregulated during oncogene-induced senescence 
and antagonized oncogenic transformation.  
 
1.3. Post-translational modifications of p53 
Unlike many transcription factors whose activities are regulated by synthesis (DNA 
 mRNA  protein), p53 undergoes numerous post-translational modifications that 
regulate its stability, activity, and, more recently described, ability to differentially activate 
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downstream targets. The p53 gene appears to be constitutively expressed under normal 
physiological conditions, and little is known about whether any mechanism exists to 
regulate p53 gene transcription. In unstressed cells, however, the p53 protein level is 
kept at a low steady-state level through ubiquitination of various lysine residues on p53 
by E3-ligase Mdm2 and subsequent ubiquitin-mediated proteosomal degradation [57]. 
Classically, p53 is activated in a three-step process after stress induction. First, p53 
is phosphorylated by several kinases, including ATM/ATR/DNA-PK and Chk1/Chk2, 
which stabilizes p53 by dissociating p53 from its negative regulator Mdm2 [58-60]. 
Second, stabilized p53 then binds DNA promoters of its downstream target genes. 
Finally, DNA-bound p53 recruits transcriptional machineries and co-activators to activate 
transcription of p53 targets. However, recent findings revealed that p53 regulation at the 
post-translational level are far more complex, which includes a wide array of 
modifications such as ubiquitination, phosphorylation, acetylation, methylation, 
sumoylation and neddylation (Figure 1.3). 
 
1.3.1. Phosphorylation 
Phosphorylation of serine residues on the N-terminal transactivation domain of p53 


















Figure 1.3. Post-translational modifications of p53. The p53 protein is subjected to a 
vast number of modifications that regulates and fine-tunes its activity and stability, 
including phosphorylation, ubiquitination, acetylation, methylation, sumoylation and 








(Ser18 in mouse) and Ser20 (Ser23 in mouse) by ATM/ATR/DNA-PK and Chk1/Chk2 
kinases was generally thought to be the initial step in p53 activation, which inhibits p53 
interaction with Mdm2 [58-60]. Unbound from Mdm2, p53 is thought to be stabilized and 
readily available to bind DNA and activate transcription. 
However, knock-in mouse model that expresses phosphorylation-deficient p53 
mutant at Ser18 and/or Ser23 cast doubt on the significance of phosphorylation in p53 
activation [61-64]. Using serine-to-alanine point mutations at the N-terminal serine 
residues of p53, studies showed that single mutations at Ser18 or Ser23 exhibit only 
modest effects on p53 transcriptional activity, while the degree of p53 stabilization in the 
mutants is comparable to that of wild-type. 
Interestingly, double-mutant mouse model at Ser18/Ser23 revealed greater defect in 
both p53 level and function, suggesting a synergetic role of these two phosphorylation 
sites in p53 activation [65]. Nevertheless, the defects observed were not universal in the 
entire organism, but rather, exhibit in a tissue-specific manner. For example, the 
transcriptional defects of p53 were mostly limited to thymocytes, while mouse embryonic 
fibroblasts (MEFs) and other tissues remain unaffected. Furthermore, several studies 
also demonstrated that p53 can be activated in the absence of N-terminal 
phosphorylation, suggesting that p53 activation involves a much more complex 
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regulatory network beyond p53 phosphorylation [66-68]. 
 
1.3.2. Ubiquitination 
Cellular levels of p53 are tightly regulated to avoid unwanted toxic effects of p53 
under non-stressed physiological conditions. Regulation of p53 level is predominantly 
accomplished through ubiquitin-mediated proteasomal degradation. The p53 protein can 
be poly-ubiquitinated on lysine residues by several E3-ligases, including Mdm2, COP1, 
Pirh2, and Arf-BP1 [69-74]. The six C-terminal lysine residues of p53 were first identified 
to be heavily ubiquitinated by Mdm2 that led to p53 degradation [75]. However, knock-in 
studies using mouse model with lysine-to-arginine mutations of the C-terminal lysine 
residues (p53-6KR) showed that the 6KR mutant p53 does not display enhanced stability 
[76]. Similarly, p53-7KR knock-in mice (seven lysine residues on C-terminal of mouse 
p53 instead of six lysines on human p53) demonstrate comparable p53 half-life when 
compared to wild-type mice [77]. These studies established that C-terminal ubiquitination 
of p53 by Mdm2 is not essential for p53 degradation. Indeed, evidence showed that 
lysine residues in the DNA-binding domain and the N-terminal may also be ubiquitinated 
for proteasomal degradation [78]. Additionally, p53 is found to be degraded in the cells of 
Mdm2-null mice, suggesting that other E3-ligases such as COP1, Pirh2, and Arf-BP1 
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can contribute to the overall control of p53 levels in cells [79]. 
Aside from poly-ubiquitination, p53 can also undergo degradation-independent 
mono-ubiquitination that promotes p53 nuclear export and p53 localization in the 
cytoplasm [80]. Recent evidence showed that cytoplasmic and mitochondrial p53 play 
important roles in mediating functions such as apoptosis and autophagy [48,81]. 
 
1.3.3. Acetylation 
Although acetylation was previously known to only occur on histones, p53 became 
the first non-histone protein to be functionally regulated by acetylation on lysine residues. 
The first histone acetyltransferase discovered to acetylate p53 was CBP/p300, and loss 
of function mutations of CBP/p300 were found in several human cancers [82,83]. 
CBP/p300 acetylates p53 at the six lysine residues of the C-terminal regulatory domain, 
which results in the activation of p53 sequence-specific DNA binding [84]. An in vivo 
model of acetylation-deficient p53-6KR knock-in mice showed impaired p53-dependent 
gene expression in embryonic stem cells and thymocytes after DNA damage, supporting 
the notion that C-terminal acetylation activates transcriptional activity of p53 [76]. In 
addition, acetylation of p53 competes with ubiquitination of the same lysine residues by 
Mdm2 and other E3 ligases, thereby stabilizing p53 and to preventing its 
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proteosome-mediated degradation [85].  
That acetylation of p53 is a crucial mechanism of p53 regulation is further supported 
by evidence that p53 is deacetylated by deacetylases HDAC1 and Sir2α/Sirt1, and that 
this reversal of acetylation status significantly represses p53-dependent transcriptional 
activation. Deacetylation of p53 by the HDAC1 complex modulates apoptosis and growth 
arrest in cells, and Sirt1-mediated p53 deacetylation represses p53-dependent apoptosis 
in response to DNA damage and oxidative stress [86-88].  
However, while the model that p53 C-terminal acetylation is important in regulating 
p53 transcriptional activity and the downstream effects of apoptosis and cell growth 
arrest is well-supported by in vitro biochemical studies and certain evidence from an in 
vivo mouse model, the same mouse model also raised concern that the significance of 
C-terminal acetylation may not be global. Even though, as previously mentioned, 
embryonic stem cells and thymocytes exhibited dramatic effects from the inability to 
acetylate C-terminal lysine residues of p53, embryonic fibroblasts derived from the same 
p53-6KR mice did not show any significant differences from that from wild-type mice [76]. 
This suggests that C-terminal acetylation may have cell-specific regulatory effects, rather 
than a general impact on apoptosis or cell cycle control.  
In addition to CBP/p300, p300/CBP-associating factor (PCAF) is another 
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acetyltransferase that acetylates p53 at lysine K320 [89,90]. Acetylation of K320 was 
found to be increased after DNA damage and enhanced DNA-binding of p53 to target 
promoters. However, analysis of the K317R (analogous to K320 in human) p53 mutant 
mice revealed unexpected results. Instead of disrupting the activation of p53, the K317R 
mutant p53 appeared to increase the expression of pro-apoptotic genes in mouse 
thymocytes and intestinal epithelial cells, indicating that the function of the K320 
acetylation may be more complex than previously hypothesized [91]. 
Although the lysine mutant knock-in mouse model casts doubt on the importance 
of C-terminal acetylations, recent studies have shown that p53 acetylation is not limited 
to the C-terminal domain. Two independent studies showed that the lysine residue K120 
of the DNA-binding domain is acetylated by two different acetyltransferases – Tip60 and 
hMOF [92,93]. Tip60 and hMOF belong to the MYST family of acetyltransferases that 
share no homology with the CBP/p300 acetyltransferases. The K120 lysine residue is 
conserved in all species with functional p53 gene, implying that acetylation at this site 
may play an evolutionarily conserved role. More importantly, Tip60 was identified as a 
p53 activator from a large-scale RNA interference screen [94]. 
Acetylation of the K120 site is essential for the p53-mediated apoptotic response to 
DNA damage. Expression of the proapoptotic target genes Puma and Bax requires the 
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K120 acetylation of p53, while expression of p21 and Mdm2 do not. When the K120 
lysine residue is mutated to arginine, p53-mediated expression of Puma and Bax genes 
are impaired, while the expression of Mdm2 is not affected and that of p21 gene is only 
slightly decreased. Furthermore, chromatin-immunoprecipitation (ChIP) using wild-type 
p53 and acetylation-deficient mutant p53-K120R showed that both wild-type and mutant 
p53 are recruited to the promoters of Puma, Mdm2 and p21 equally, implying that the 
K120 acetylation does not affect DNA binding ability of p53 [93]. 
 Another recently identified acetylation site in the DNA-binding domain is K164, 
acetylated by CBP/p300 [95]. Simultaneous loss of acetylation at K164, K120, and the 
six C-terminal lysine residues (p53-8KR) completely abolishes the ability of p53 to 
induce p21 expression and cell cycle arrest. However, loss of acetylation individually at 
the aforementioned lysine residues still allows p53 to activate p21, suggesting that these 
acetylation sites may compensate one another through redundancy. Notably, the 
p53-8KR mutant retains DNA-binding capabilities and is able to transactivate the Mdm2 
negative-feedback loop. 
 
1.3.4. Methylation, Sumoylation, and Neddylation 
Lysine residues are very versatile in their ability to be post-translationally modified. 
22 
 
Besides ubiquitination and acetylation, as previously described, lysine residues on p53 
can also undergo methylation, sumoylation and neddylation. 
Three different methyltransferases have been reported to methylate p53 on the 
C-terminal lysine residues. Monomethylation by Set7/9 at lysine K372 promotes p53 
activity and enhances transactivation of p21 [96]. On the other hand, monomethylation at 
K370 and K382 by Smyd2 and Set8/PR-Set7, respectively, represses p53 transcriptional 
activity [97,98]. Interestingly, K370 of p53 can also be dimethylated, although by an 
unknown methyltransferase, and the dimethylated lysine residue act as an anchor for 
binding to co-activator 53BP1 (p53-binding protein 1). Demethylase LSD1 preferentially 
removes the dimethylation on K370, and thereby, inhibits the interaction between p53 
and 53BP1 and represses p53 activity [99]. 
Sumoylation is the addition of ubiquitin-like SUMO substrate on lysine residue. p53 
has been shown to be sumoylated at K386. While one study demonstrated that 
sumoylation activates p53, another study reported that this modification promotes 
cytoplasmic localization of p53 [100,101]. 
Neddylation, on the other hand, appears to inhibit p53 transcriptional activity. 
Neddylation, the conjugation of ubiquitin-like NEDD8 molecule, can be mediated by 
Mdm2 at lysine residues K370, K372, and K373 [102]. In another study, neddylation was 
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observed at K320 and K321 by FBXO11 [103]. 
 
1.4. Mechanism of p53-mediated tumor suppression 
Although the molecular mechanism of how p53 achieves tumor suppression is not 
entirely understood, it has long been accepted that tumor proliferation can be inhibited by 
p53-mediated apoptosis, cell growth arrest and senescence. Indeed, pausing cell cycle 
progression to repair DNA damage or ultimately terminating a cell harboring irreversible 
genotoxic damage do prevent the accumulation of oncogenic mutations in an organism. 
However, recent evidence suggests that tumor suppression by p53 can be achieved in 
the absence of p53-mediated apoptosis, cell growth arrest and senescence. 
 
1.4.1. Apoptosis and growth arrest are not essential in tumor suppression 
The earliest evidence came from the analysis of the p21/WAF1 knock-out mouse 
model in which no spontaneous tumorigenesis was observed [104,105]. This may not 
come as a surprise, as apoptotic functions of p53 may very well compensate for the lack 
of growth arrest. Later studies also failed to observe any increased tendency in tumor 
formation in apoptosis-deficient Puma and Noxa double knock-out mice, possibly due to 
intact growth arrest function [23,106]. Surprisingly, however, the p533KR/3KR knock-in 
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mice (loss of acetylation at lysine residues K117 and K161/162 via replacement with 
arginine), which exhibit defects in both p53-dependent apoptotic and cell cycle arrest 
response, do not present with significantly earlier onset of tumorigenesis compared with 
wild-type mice [107]. While p53-null mice succumb to early onset of thymic lymphomas 
before the age of 6-months, most p533KR/3KR mice remain healthy up to 16-months of age. 
These studies suggest that properties of p53 other than apoptotic and growth arrest 
functions may contribute to p53-mediated tumor suppression. Interestingly, p533KR/3KR 
mice retain the ability to regulate certain metabolic genes, including TIGAR and GLS2. 
Recent evidence has implicated p53 metabolic targets, such as TIGAR and GLS2, in 
tumor suppression through their ability to modulate the metabolic state of cancer cells 
[37,39].  
Similarly, mouse model containing mutations in an N-terminal transactivation 
domain at residues 25 and 26 (p5325,26/25,26) fail to upregulate downstream apoptotic and 
growth arrest targets, but retain the ability to prevent tumorigenesis [108]. Finally, triple 
knock-out mice deficient in p21, Puma and Noxa expressions do not develop 
spontaneous tumors [109]. Collectively, these pieces of evidence underscore the 




1.4.2. Role of p53 metabolic regulation in tumor suppression 
As described in previous sections, p53 metabolic targets have functions that 
counteract the metabolic alterations commonly seen in cancer cells. Indeed, as evident 
in the p533KR/3KR mice, metabolic regulation by p53 could potentially play critical role in 
suppressing tumor formation [107]. However, with yet another twist in this convoluted 
story, p53 metabolic targets may not always function as tumor suppressors. 
Evidence supporting p53 metabolic targets as tumor suppressors showed that loss 
of GLS2 expression correlates with neoplastic transformation in human hepatocellular 
carcinomas [36,37], while low SCO2 expression is a factor of poor prognosis in patients 
with breast cancer [110]. The rationale behind this is two-fold: 1) cancer cells display a 
heightened state of aerobic glycolysis that confers several growth advantages over 
normal cells, and p53 targets such as SCO2, TIGAR and GLS2 may contribute to 
p53-mediated tumor suppression by preventing such metabolic transformation; and 2) 
upregulation of antioxidant production by p53 metabolic targets prevents the increase in 
oxidative stress associated with malignant transformation. 
On the other hand, while aerobic glycolysis promotes rapid growth in tumors, it is not 
without pitfalls. The inefficiency of glycolysis for energy generation could become 
perilous for cancer cells that have outgrown the resource capacity of their tumor 
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environments. Similarly, although cancer cells generally have increased levels of ROS, 
which perpetuates cell proliferation and are involved in tumor initiation and progression, 
excessive accumulation of ROS is also toxic to cancer cells. Evidence showed that 
cancer cells require robust antioxidant capacity to offset the intrinsic oxidative stress for 
survival [111-114]. Given that p53 metabolic targets have the capability of modulating 
energy homeostasis and decreasing intracellular ROS levels, they could potentially 
support cancerous growth under certain circumstances. Nevertheless, precisely how 
these targets affect tumorigenicity or survival of cancer cells remains elusive. 
Recent studies have attempted to further our understanding of the function of p53 
metabolic targets in the context of tumor biology, but the findings only broadened the 
complexity of tumor metabolism. Current evidence demonstrates that certain cancers 
gain survival advantages by retaining wild-type p53 and the subsequent activation of p53 
metabolic targets. Wanka et al. showed that glioma and colon cancer cells that express 
wild-type p53 are less sensitive towards hypoxia-induced cell death [115]. These cancer 
cells were able to maintain mitochondrial respiration under hypoxic conditions through 
the activation of SCO2, while cells depleted of p53 or SCO2 undergo necrotic cell death 
in the presence of low oxygen [115]. TIGAR is also reported to have tumor-protective 
functions as well. Cheung et al. reported that TIGAR plays a role in enhancing intestinal 
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adenoma proliferation as well as regeneration of intestinal epithelium [116]. Through 
several rescue-experiments, the authors concluded that Tigar expression prevents ROS 
accumulation through increasing GSH:GSSG ratio and increases nucleotide synthesis 
that allow intestinal tumor cell to grow more efficiently. Indeed, tumor burden is 
decreased in TIGAR knock-out mice compared to TIGAR wild-type mice using an 
intestinal adenoma mouse model [116]. Similarly, another study by Wanka et al. revealed 
that Tigar expression protects glioma cells from glucose starvation and hypoxia-induced 
cell death, which coincides with TIGAR been overexpressed in glioblastomas [117]. 
Together, these studies provide evidence that p53 may protect tumor cells from their 
harsh microenvironment or oxidative stress through the regulation of metabolic targets, 
which are also suggested by previous studies [118,119]. 
These findings present a rather puzzling question – does p53 suppress tumor 
formation or does it enhance tumor cell survival? The answer, it seems, is that p53 may 
act as a double-edged sword (Figure 1.4). While metabolic functions of p53 do indeed 
contribute to the overall tumor suppressing activity of p53, they also serve to protect cells, 
normal or tumor alike, from metabolic stress. By lowering ROS levels and maintaining 
energy homeostasis, p53 metabolic targets may avert crises that would otherwise result 











Figure 1.4. Opposing functions of p53 metabolic regulation. Metabolic regulation by 
p53 in tumorigenesis is a double-edged sword: maintaining oxidative balance and 
energy homeostasis could prevent cancer development in the pre-cancerous stage, but 








survival, cancer cells have an even lower threshold for oxidative insults [34]. In order for 
tumor cells to thrive, they must upregulate pathways for antioxidant production, many of 
which are controlled by p53 targets. Moreover, tumor cells often suffer from hypoxic and 
nutrient stress due to rapidly growing cells competing for finite amount of resources, 
especially for cells residing in the center of the tumor bulk where blood supply is limited. 
Under such conditions, tumor cells will benefit from a shift from aerobic glycolysis to the 
higher efficient oxidative phosphorylation for energy production, which is also regulated 
by p53 activity. If indeed p53 function manifests such duality, then when in the evolution 
of normal to tumor cells does p53 seizes to exist as a tumor suppressor and don the role 
of enhancing tumorigenicity? Further studies are warranted in order to dissect the 
intricate balance of cell death and survival in p53 function on tumorigenesis. 
 
1.5. Differential regulation of p53 targets 
With the ever-expanding number of p53 targets involved in a diverse array of cellular 
processes, it is crucial for p53 to selectively activate its downstream targets to achieve 
the desired outcome depending on the cellular context. Currently, the mechanism 
underlying the preferential expression of p53 targets remains largely unknown. Previous 
evidence, however, points towards the possibility that the acetylation of specific lysine 
30 
 
residues of p53 can differentially regulate the expression of pro-apoptotic and growth 
arrest genes. Acetylation of p53 at the K120 lysine residue by acetyltransferases 
Tip60/hMOF is crucial for p53-mediated apoptosis but not for cell cycle arrest [92,93]. On 
the other hand, p53 acetylation at K164 is acetylated by CBP/p300, and loss of 
acetylation at both K120 and K164 abolishes the ability of p53 to induce both apoptosis 
and growth arrest [95]. This notion is also supported by the 3KR mouse model. While 
p53-mediated apoptotic and growth arrest gene expressions are abrogated in the 3KR 
mice, expression of Mdm2 and many of the metabolic targets are still retained [107]. 
These findings suggest that additional post-translational modifications of p53 may be 
required for the preferential expression of p53 metabolic and non-canonical genes.  
Given our current knowledge, we hypothesize that the regulation of downstream 
targets by p53 may be hierarchical in nature (Figure 1.5). Depending on the severity and 
the type of stress in question, specific sites and number of p53 modifications may vary in 
which to dictate the appropriate p53 response. Under no or low stress conditions, 
minimal post-translational modifications of p53 may be sufficient to activate targets such 
as Mdm2 and various metabolic genes. In the absence of stress, expression of Mdm2 is 
required to negatively regulate p53 activity in order to avoid p53-induced cell death. 











Figure 1.5. A hypothetical model of differential regulation by p53. p53 is subjected 
to a hierarchical sequence of post-translational modifications as stress level increases, 
which induces various functional outcome depending on the combination of 








metabolic targets could enhance cell adaptation and survival. Upon facing moderate 
stress, however, p53 acetylation increases at K164 and C-terminal lysine residues that 
lead to growth arrest via p21 induction, which allow cells to recover and repair cellular 
damage. Ultimately, if the damage from stress becomes irreparable, acetylation at the 
K120 site would trigger an apoptotic response to circumvent the perpetuation of possible 
genetic lesions. 
The rationale underlying our hypothesis is that p53 metabolic targets, unlike its 
canonical counterparts involved in apoptosis and growth arrest, are relatively harmless in 
nature and serve to improve cellular homeostasis, and therefore, are subjected to a 
hierarchical regulation. This would allow the selective expression of metabolic genes and 
Mdm2 in the presence of basal p53 expression under normal growth without activating 
other p53 functions. It is also possible that p53 targets functioning in oxidative balance 
and autophagy may be regulated in a similar fashion. Since mounting evidence suggests 
that non-canonical functions of p53 are critical in tumor suppression and/or cell survival 
and homeostasis, elucidating the minimal modifications for activating p53 non-canonical 
targets could be the key to understanding the mechanism of how p53 participate in 
















2.1. Chapter 1: p53-dependent regulation of metabolic function through 
transcriptional activation of pantothenate kinase-1 gene 
2.1.1. Background and Rationale: 
The p53 protein is a tumor suppressor whose primary function is to maintain the 
integrity of the genome through cell fate control [1] (see Section 1.1). Classically, p53 is 
activated under genotoxic stress and acts as a transcription factor to regulate the 
expression of downstream apoptotic or growth-arrest targets [13,14]. However, recent 
works have shown that functions of p53 go far beyond cell death and growth arrest, and 
now also include metabolism, autophagy, senescence and aging [24,25] (see Section 
1.2).  
Proper metabolic function is crucial to the viability of normal cells. Interestingly, 
metabolism also plays a key role in the adaptability of neoplastic cells, the process of 
tumorigenesis, and genome stability, and p53 has been recently linked to these aspects 
of metabolic functions [120]. p53 has been shown to regulate the balance between 
glycolysis and mitochondrial respiration through transcriptional control of several 
metabolic genes. SCO2 gene, a transcription target of p53, codes for a protein that 
assembles and regulates the cytochrome C oxidase complex of the electron transport 
chain. Synthesis of the Sco2 protein increases cellular mitochondrial respiration as a 
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mean of energy production, while decreasing the need for glycolysis. Interestingly, loss 
of p53 in cancer cells correlates with decreased SCO2 expression, which leads to a shift 
of energy production towards glycolysis, a phenomenon known as the Warburg’s Effect 
[35]. p53 also represses the expression of glucose transporters GLUT1/3/4, thereby 
decreasing cellular uptake of glucose and subsequent glycolysis [40]. In addition, p53 
negatively regulates the transcription of the pyruvate dehydrogenase kinase PDK2, 
which phosphorylates and inhibits pyruvate dehydrogenase (PDH). By relieving the 
inhibitory effect on PDH, p53 facilitates the conversion of pyruvate into acetyl-CoA by 
PDH as substrate for mitochondrial respiration [121]. 
Furthermore, p53 has been implicated in metabolic pathways that regulate the 
synthesis of cellular antioxidant glutathione, which protects cells against reactive oxygen 
species (ROS). TIGAR, a p53 target, inhibits glycolysis by decreasing the level of 
fructose-2,6,-bisphosphate and shunts glucose into the pentose phosphate pathway for 
NADPH production that leads to glutathione recycling [39]. To a similar effect, p53 can 
upregulate the expression of glutaminase GLS2, which converts glutamine to glutamate 
for glutathione synthesis [36,37]. 
Aside from genotoxic stress, cells may also activate p53 under metabolic stress. 
Studies have shown that p53 is induced under energy and nutrient deprivation by 
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energy-sensing AMP-activated protein kinase (AMPK), and may lead to subsequent 
activation of growth arrest pathways [122,123]. In addition, p53 also induces autophagy 
in the face of prolonged starvation to generate sufficient energy for survival through 
regulation on LC3 [124]. Together, these evidence suggest that p53, besides being a 
tumor suppressor, may also play a prosurvival role of maintaining metabolic homeostasis 
under energy crisis. 
In light of these recent evidence that point towards the significance of p53 in 
metabolic regulation, we performed a chromatin-immunoprecipitation-on-chip 
(ChIP-on-chip) analysis using p53 as bait and identified pantothenate kinase-1 (PANK1) 
as a potential metabolic target of p53. PanK1 is a member of a family of proteins (PanK 
family) that are involved in the biosynthesis of coenzyme A (CoA). CoA is an essential 
and ubiquitous cofactor that is obligatory in over 100 different intermediary metabolic 
reactions, including those involved in fatty acid metabolism, tricarboxylic acid cycle, and 
cholesterol and bile acid synthesis. The PanK family of proteins catalyze the first and 
rate-limiting step of CoA synthesis (phosphorylation of precursor pantothenate), and thus 
control the cellular content of CoA [125]. 
There are two PanK isoforms encoded by the PANK1 gene, PanK1 and PanK1, 
and two other isoforms (PanK2 and PanK3) encoded by two other distinct genes. PanK1 
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is most highly expressed in the liver, and corresponds to the liver possessing the highest 
concentration of CoA among tissues [126]. This is consistent with the fact that a plethora 
of tissue-specific metabolic functions of the liver require CoA, which includes β-oxidation, 
ketogenesis, gluconeogenesis, and sterol synthesis. CoA levels in tissues, especially in 
the liver, change under metabolic stress in order to utilize alternative fuel sources to 
meet energy demands. In cases such as starvation and diabetes, increase in the liver 
intracellular CoA concentration is required to promote sufficient conversion of stored fatty 
acids and amino acids into ketone bodies and glucose to supply the rest of the body 
[127]. 
Here, we report that PanK1 is a transcriptional target of p53, but does not contribute 
to p53-dependent apoptosis or growth arrest. Instead, we observed that p53 is required 
to maintain PanK1 expression in vitro after glucose starvation and in the mouse liver 
during fasting. In the absence of p53, PanK1-dependent CoA synthesis decreases, 
leading to impediment of catabolic and anabolic processes in the liver. 
 
2.1.2. Materials and Methods: 
Cell Culture, Transfection, siRNA-Mediated Knockdown and Antibody. H1299 and 
U2OS cells were maintained in DMEM and HCT116 cells in McCoy’s 5A medium. All 
38 
 
media were supplemented with 10% fetal bovine serum. Transfections with plasmid DNA 
and siRNA were performed using Lipofectamine2000 (Invitrogen) according to the 
manufacturer’s protocol. Ablation of PanK1 was performed by transfection of HCT116 
cells with siRNA duplex targeting human PanK1 mRNA (5’ – 
GUGGAACGCUGGUUAAAUU – 3’). The rabbit polyclonal antibody specific for PanK1 
protein was produced in collaboration with Bethyl Laboratories, Inc. 
 
Chromatin Immunoprecipitation (ChIP). Adherent cells were incubated in culture 
media containing 1% formaldehyde with gentle shaking for 10 min at room temperature, 
and crosslinking was stopped by addition of 2.5 M glycine to a final concentration of 
0.125 M glycine. After two washes with cold PBS, cells were harvested in ice cold lysis 
buffer (10 mM Tris-Cl [pH 8.0], 85 mM KCl, 0.5% NP-40, 5 mM EDTA, 0.25% Triton-X, 
and fresh proteinase inhibitor cocktail) and incubated on ice for 10 min. Nuclei were 
collected, suspended in cold RIPA buffer (10 mM Tris-Cl (pH 8.0), 150 mM NaCl, 0.1% 
SDS, 0.1% DOC, 1% Triton X-100, 5 mM EDTA, and fresh proteinase inhibitor cocktail), 
and sonicated to shear the genomic DNA to an average of 300 bp. Cleared extracts were 
blocked with protein A beads (Millipore), and p53 proteins were immunoprecipitated by 
FL-393 p53 antibody (Santa Cruz) followed by binding of antibodies to protein A beads. 
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After eight washes by RIPA buffer with gentle rotation for 5 min each time, the proteins 
were eluted from the beads by 0.5 mL elution buffer (30 mM Tris-Cl [pH 8.0], 15 mM 
EDTA, 200 mM NaCl and 1% SDS). The DNA samples were recovered by phenol 
extraction and ethanol precipitation after reversal of crosslinking. The purified DNA were 
then analyzed either by PCR within linear amplification range followed by agarose gel 
electrophoresis or by quantitative real-time PCR using Applied Biosystems 7500 Fast 
System. The following primers were used for PanK1 ChIP: forward primer 5’ – 
CGATGCCCATCTGGTTTTCACATCG – 3’ and reverse primer 5’ – 
GCCACCGACGAGTTTCAACA – 3’.  
 
Luciferase Activity Assay. Promoter-containing fragments were amplified from human 
genomic DNA of H1299 cells and cloned into the pBVLuc luciferase reporter vector 
containing a minimal promoter (He et al., 1998). To test the potential p53 binding sites, 
fragment for pLucA containing the p53 BS was amplified using forward primer 5’ – 
GATGCCGCCTTCCCTTCTTA – 3’ and reverse primer 5’ – 
GAGGAAGCCGCGTTTGAAGT – 3’, while fragment for pLucB without the p53 BS was 
amplified using the same forward primer and reverse primer 5’ – 
CATCGCCATACAAAGCCCAA – 3’. Mutations of the various p53 binding sites were 
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generated using site-directed mutagenesis with the following oligos: 5’ – 
CCCATCTCCTCTCTGTAATCCCAGAGAACTTGAT – 3’ and 5’ – 
ATCAAGTTCTCTGGGATTACAGAGAGGAGATGGG – 3’ for pLucA’1, 5’ – 
CCAGAGAATTTTATTCCCTATATTGAAACTCGTCGGTGGC – 3’ and 5’ – 
GCCACCGACGAGTTTCAATATAGGGAATAAAATTCTCTGG – 3’ for pLucA’23, and 5’ – 
GGCGGTGGCGGGTAGTACTGGGAATTCTCAGTGGCGGG – 3’ and 5’ – 
CCCGCCACTGAGAATTCCCAGTACTACCCGCCACCGCC – 3’ for pLucA’45. 
Transfection of H1299 cells were performed in 24-well plate using 0.2 g luciferase 
reporter constructs, 0.05 g pRL-tk Renilla construct, and various amount of 
p53-expressing vector. Luciferase activities were measured 24 hrs post-transfection 
using Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activities 
were normalized with Renilla luciferase activities to obtain the relative luciferase activity. 
 
Gel Mobility Shift Assay (EMSA). Purified Flag-p53 proteins were obtained from 
transfected 293 cells. The 171-bp DNA probe containing the p53 binding sites were 
PCR-amplified from PANK1 promoter using primers 5’ – CTGTCTCTCCCAGACCCAT – 
3’ and 5’ – AGTCTGGGAGGCGAGGAAG – 3’, labeled by T4 kinase (NEB, M0201S) 
and purified using the Bio-Spin 30 columns (Bio-Rad). The protein-DNA binding 
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reactions (20 μl) contained 20 mM HEPES (pH 7.6), 80 mM NaCl, 0.1 mM EDTA, 12.5% 
glycerol, 2 mM MgCl2, 2 mM spermidine, 0.7 mM DTT, 200 ng/μL BSA, 20 ng/μL sheared 
sperm DNA, 10–20 fmol DNA probe, and 200 ng Flag-p53. In supershift assays, 200 ng 
pAb421 (Millipore) antibody was added to the reaction. Wild-type and mutant competition 
probes were PCR-amplified from pLucA and pLucA’2345, respectively, using the above 
primers.  
 
RNA Extraction and RT-qPCR. Total RNA was extracted using TRIzol Reagent (Life 
Technologies) according to the manufacturer’s protocol. cDNA was synthesized from 
total RNA using M-MulV Reverse Transcriptase kit (NEB). PCR analysis was carried out 
using Applied Biosystems 7500 Fast System with the following primers: 5’ – 
CGCTGCGAAATACACCAATTTAACCAGCG – 3’ and 5’ – 
AAGAACAGGCCGCCATTCC – 3’ for human PanK1, and 5’ – 
ACAGGACGCTGTGGGATGTAAA – 3’ and 5’ – 
CGCTGCGAAATACACCAATTTAACCAGCG – 3’ for human PanK1. 
 
PanK Activity Assay. Enzyme preparation and assays were performed as described 
previously (Vallari et al., 1987). The pantothenate kinase specific activities in cell lysates 
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were calculated as a function of protein concentration measured by Bradford method. 
Assays contained d-[1-14C]-pantothenate (45.5 μM; specific activity 55 mCi/mmol), ATP 
(2.5 mM, pH 7.0), MgCl2 (2.5 mM), Tris–HCl (0.1 M, pH 7.5), and increasing amounts of 
cell extract in a total volume of 40 μL. The mixture was incubated for 10 min at 37°C and 
the reaction was stopped by depositing a 30 μL aliquot onto a Whatmann DE81 
ion-exchange filter disk that was washed with 1% acetic acid in 95% ethanol (25 ml/disk) 
three times to remove non-reacted pantothenate. 4’ – Phosphopantothenate was 
quantified by counting the dried disk in 3 mL scintillation solution. 
 
Free CoA and Long-Chain Acyl-CoA Measurements. Extraction of free CoA and long 
chain acyl-CoA were performed as described previously. Briefly, 100 mg of mouse tissue 
was homogenized in 0.4 mL chilled 6% perchloric acid containing 28 mM DTT. After 
centrifugation (1500 × g, 4°C, 10 min), the precipitate contains the acid-insoluble 
long-chain acyl-CoAs, while the supernatant contains the acid-soluble free CoA. For free 
CoA extraction from the supernatant, 0.1 volume of 1 M Tris and 0.3 volume of 2 M KOH 
were added before the pH was adjusted to 6.5∼8.5 with 0.6 N HCl. The mixture was 
centrifuged (1500 × g, 4°C, 10 min) and the supernatant was saved for CoA 
determination. For long-chain acyl-CoA extraction, the precipitated pellet was washed 
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with 0.6% perchloric acid containing 5 mM DTT and then washed with 5 mM DTT. The 
washed pellet was resuspended in 300 μL of 5 mM DTT and the pH was adjusted to 
11∼12 with 1 M KOH. The mixture was incubated at room temperature for 1 hr, 
neutralized with 0.6 N HCl to pH 6.5∼8.5, and centrifuged (1500 × g, 4°C, 10 min). The 
resultant supernatant was extracted with an equal volume of hexane three times before 
being used in the CoA determination assay. The reaction mixture for the CoA 
determination assay contained 200 mM Tris-HCl (pH 7.5), 8 mM MgCl2, 0.1% Triton 
X-100, 2 mM EDTA, 20 mM NaF, 2.5 mM ATP, 10 μM [1-14C]lauric acid, 100 ng of E. coli 
acyl-CoA synthetase (FadD), and tissue extract (5–20 μL) in a total volume of 100 μL. 
The reaction was initiated by the addition of FadD, and the reaction mixture was 
incubated at 35°C for 30 min, followed by the addition of 325 μL of 
methanol:chloroform:n-heptane (1.41:1.25:1, v/v/v) and 25 μL of 0.4 M acetic acid. After 
the mixture was mixed vigorously and centrifuged, [1-14C]lauroyl-CoA in the upper phase 
was quantified by counting in 3 mL scintillation solution. 
 
Oil Red O Staining. ORO staining was performed by Columbia University HICCC 
Histology Services. The mouse liver frozen sections were cut at 7 m thickness and fixed 
in 10% formalin before staining with Oil Red O solution and Hematoxylin. 
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Pyruvate Challenge Test and Blood Glucose Measurements. For the pyruvate 
challenge test, mice were starved for 16 hrs and were then intraperitoneally injected with 
pyruvate dissolved in saline (2 mg/g of body mass). Blood glucose was measured using 
OneTouch Ultra Blue Test Strips (LifeScan Inc.). 
 
2.1.3. Results and Discussion: 
PANK1 gene is a p53 transcriptional target 
PANK1 promoter was identified in a ChIP-on-chip assay using p53-transfected 
H1299 cells. The potential p53 binding site (BS) on PANK1 promoter was approximated 
to the 5’-end of exon 1 of PANK1α isoform (Figure 2.1). To verify the binding of p53 to 
the PANK1 promoter, we carried out chromatin-immunoprecipitation (ChIP) in H1299 
cells transfected with p53 expression vector, followed by quantitative real-time PCR 
(qPCR) amplification of the pulled-down DNA fragments. The relative p53 enrichment at 
the potential PANK1 p53 BS was similar to those at promoters of well-established p53 
metabolic targets (TIGAR, SCO2, and GLS2), while no enrichment was detected at the 
region 2kb upstream of the potential PANK1 p53 BS, proving that p53 indeed binds to 
the PANK1 promoter (Figure 2.2). 












Figure 2.1. Schematic representation of the human PANK1 gene and its promoter. 
The potential p53 binding sites (p53 BS) are located in the 5’ region of PANK1 exon 1. 
TSS represents the transcriptional start site. Luciferase construct pLucA containing the 
p53 BS and construct pLucB lacking the p53 BS are derived from the potential PANK1 
promoter region for luciferase reporter gene assays in C and D. In addition, luciferase 
constructs containing mutations of the potential p53 consensus sequences are denoted 


















Figure 2.2. Validation of p53 binding on PANK1 promoter. The left panel shows 
ChIP-qPCR analysis of p53 enrichment at the promoter regions of PANK1, TIGAR, 
SCO2, GLS2, and p21 in H1299 cells expressing p53. GAPDH and a region located 2-kb 
upstream of the PANK1 p53 BS were used as negative controls. The right panel shows 







transcription through the PANK1 promoter using luciferase assay. Luciferase constructs 
pLucA containing Fragment A of PANK1 promoter (as depicted in Figure 2.1) with the 
potential p53 BS and pLucB containing Fragment B without the p53 BS were generated. 
Co-transfection of pLucA with WT p53 expression vector into p53-null H1299 cells 
increased luciferase activity in a p53 dose-dependent manner, while co-transfection with 
binding-deficient mutant p53-R175H failed to do so (Figure 2.3A). Interestingly, 
co-transfection of pLucB with p53 expression vector did not induce reporter activity, 
confirming that the potential p53 binding site is indeed at the predicted region. 
Five potential p53 binding half-sites (BHS) were found at the 5’ region of PANK1 
exon1α that overlaps with the translational start site (Figure 2.1). Mutation of each BHS 
was generated by mutating the most conserved C/G to A/T (RRRCWWGYYY  
RRRAWWTYYY) in pLucA. Mutation of BHS 1 did not reduce transcriptional activity in 
the presence of p53, while mutations of BHS 2+3 and BHS 4+5 significantly reduced 
p53-dependent transcriptional activity (Figure 2.3B). Furthermore, mutating all four 
binding half-sites completely abrogated reporter transcriptional activity by p53 (Figure 
2.3B). 
We next performed gel mobility shift assay to determine whether p53 binds to the 






Figure 2.3. Promoter binding assays confirming p53-binding of PANK1 promoter. 
(A) p53 activates luciferase activity of reporter construct containing p53-binding 
elements in the PANK1 promoter. H1299 cells were transfected with control vector 
(pCIN4), increasing amounts of p53 expression vector, or vector expressing 
binding-deficient p53 mutant R175H along with luciferase constructs pLucA or pLucB for 
24 hr before measuring luciferase activity. (B) Mutations of p53-binding elements on the 
reporter construct abolished p53-induced luciferase activity. H1299 cells were 
co-transfected with p53 expression vector and various mutated luciferase constructs for 
24 hr before measuring luciferase activity. (C) Gel shift assay showing p53 binding on 
oligonucleotide containing p53-binding sites in the PANK1 promoter region. The DNA 
binding activity of purified p53 protein was enhanced with C-terminal p53 antibody 
pAb421. Specificity of the binding was verified by competition with non-radiolabeled 
wild-type and mutant probes. 
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171-bp DNA fragment containing the four WT BHS, which was supershifted and 
enhanced in the presence of anti-p53 antibody (ab 421) (Figure 2.3C). Furthermore, 
binding of p53 to the radiolabeled fragment was outcompeted by the cold WT fragment, 
but not by the cold mutant fragment (Figure 2.3C). Together, these results indicate that 
the PANK1 gene is a transcriptional target of p53 and that the two consensus 
p53-binding sites (four half-sites) at the 5’-end of PANK1 exon 1α are responsible for 
p53-dependent PANK1 gene activation. 
 
p53 induces PanK1 expression 
To confirm that PANK1 is a p53-inducible gene, we examined PANK1 mRNA and 
protein expression in response to p53 overexpression and DNA damage. Transfection of 
p53 expression vector in H1299 cells induced mRNA level of PANK1α as well as that of 
p21, but expression levels of PANK1, PANK2 and PANK3 remain unchanged (Figure 
2.4A). Similarly, PanK1α protein level increased in a p53 dose-dependent manner in 
H1299 cells transfected with p53 expression vector, but no induction was observed in the 
presence of mutant p53 R175H (Figure 2.4B). In HCT116 cells containing endogenous 
WT-p53, induction of PanK1α protein level was observed upon treatment with 









Figure 2.4. Overexpression of p53 protein induces PanK1 expression. (A) H1299 
cells were transfected with either control or p53-expressing vectors, and mRNA were 
extracted from cells 24 hr after transfection and analyzed via RT-qPCR for PanK1 and 
p21 expressions. (B) Western blot analysis of the protein levels of PanK1, p21, p53, 
and actin in H1299 cells transfected with control vector and vectors expressing wild-type 






p53 induction. In contrast, PanK1α expression remained at the basal level in 
p53-deficient HCT116 cells, despite undergoing the same DNA-damaging treatments 
(Figure 2.5A). 
We next investigate whether p53 can regulate PanK1β expression. Our PanK1 
antibody (Bethyl) is able to detect exogenously expressed recombinant PanK1β isoform 
on Western blot, but our inability to detect endogenous PanK1β isoform in various cell 
lines tested is likely due to very low level expression of PanK1β. Moreover, PanK1β 
regulation by p53 could be cell-type specific, as suggested by the absence of PanK1β 
induction in H1299 cells in the presence of p53 (Figure 2.4A). In order to examine the 
possibility that p53 also regulates PanK1β expression, RT-qPCR was performed in 
HCT116 and U2OS cells treated with DNA damaging agents. Interestingly, PanK1 
mRNA level was induced upon DNA damage in both cell lines, similar to the kinetics 
seen for PanK1, while p53-deficient HCT116 cells fails to upregulate PanK1 
expression (Figure 2.5B and 2.5C). Together, our findings demonstrate that p53 
upregulates the expression of both PanK1 and PanK1 in vitro, although regulation 











Figure 2.5. Endogenous p53 induces PanK1 expression. (A) HCT116 p53+/+ and 
p53-/- cells were treated with 20 M Etoposide, 10 nM Actinomycin D, and 0.2 g/mL 
Doxorubicin for 12 and 24 hrs, and cell lysates were analyzed by Western using PanK1, 
p53, p21 and actin antibodies. (B) U2OS cells were treated with 20 M Etoposide and 10 
nM Actinomycin D for 8 and 24 hrs, and mRNA levels of PanK1 and PanK1 were 
analyzed via RT-qPCR. (C) HCT116 p53+/+ and p53-/- cells were treated with 10 nM 
Actinomycin D for 12 and 24 hrs, and mRNA levels of PanK1 and PanK1 were 




PanK1 is not required for DNA damage-induced apoptosis 
Since the major function of p53 is to act as a tumor suppressor that regulates cell 
fate under genotoxic stress, we wish to investigate whether PanK1 is a downstream 
modulator of p53-dependent cell cycle arrest or apoptosis. Depletion of PanK1 via siRNA 
in HCT116 cells containing WT-p53 did not have an effect on p21 induction or cleavage 
of proapoptotic effectors (caspase-3 and PARP) after actinomycin D treatment (Figure 
2.6A). Similarly, PanK1 knockdown in HCT116 cells did not have an effect on cell death 
after DNA damage, as measured by the sub-G1 population of apoptotic cells using FACS 
analysis (Figure 2.6B). Together, these results demonstrate that while both α- and 
β-isoforms of PanK1 are induced by p53, PanK1 does not modulate the effect of 
p53-dependent genotoxic stress response. 
 
p53 regulates PanK1 expression in vitro under starvation 
The link between p53 and PanK1 suggests a role for p53 in CoA metabolism. As 
previously mentioned, regulation of CoA level in tissues is critical in response to various 
metabolic stresses in order to meet energy demands. Interestingly, p53 has been shown 
to modulate growth arrest and apoptosis under glucose starvation in vitro. Upon glucose 








Figure 2.6. PanK1 is not required for DNA-damage-induced apoptosis. (A) HCT116 
p53+/+ and p53-/- cells were transfected with control of PanK1 siRNA for 36 hrs and were 
subsequently treated with 10 nM Actinomycin D for 0, 8 or 24 hrs. Total cell extracts were 
assayed for PanK1, p53, p21, cleaved PARP, cleaved caspase 3, and actin. (B) HCT116 
p53+/+ and p53-/- cells were transfected with control or PanK1 siRNA for 36 hrs and then 
treated with 10 nM Actinomycin D for 36 hrs. The cells were harvested, fixed with 
ice-cold methanol, and analyzed by flow cytometry. Cells with sub-G1 DNA content were 
scored as apoptotic cells.  
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expression of p53 targets [122,123]. Thus, it is possible that p53 regulates the 
expression of PanK1 during starvation. 
To test this hypothesis, we subjected isogenic HCT116 p53+/+ and p53-/- cells to 
glucose starvation. Upon glucose depletion, p53 levels are induced in HCT 116 p53+/+ 
cells and PanK1 expression remains unchanged. Surprisingly, PanK1 expression in 
HCT116 p53-/- cells decreased dramatically after glucose starvation in the absence of 
p53 upregulation (Figure 2.7A). To verify that p53 activity is indeed increased upon 
glucose starvation, we observed a steady increase in p53 downstream targets p21 and 
Puma as well as p53-induced apoptosis (cleaved caspase 3) in HCT116 p53+/+ cells, but 
not in p53-/- cells.  
 
p53 regulates PanK1 expression in vivo under starvation 
The link between p53 and PanK1 suggests a role for p53 in CoA metabolism. As 
previously mentioned, regulation of CoA level in tissues is critical in response to various 
metabolic stresses in order to meet energy demands. Interestingly, p53 has been shown 
to modulate growth arrest and apoptosis under glucose starvation in vitro. Upon glucose 
withdrawal, p53 is activated by the energy-sensing AMPK that leads to downstream 







Figure 2.7. p53 regulates PanK1 expression in vitro and in vivo under starvation. 
(A) HCT116 p53+/+ and p53-/- cells were glucose-starved (DMEM + 10% FBS + no 
glucose) for the times indicated. Total cell extracts were assayed for PanK1, p53, Puma, 
p21, cleaved caspase 3 and actin. (B) WT and p53-/- mice were either fed or starved for 3 
days, and total RNA was extracted from the livers (WT fed, n = 3; WT starved, n = 3; 
p53-/- fed, n = 3; p53-/- starved, n = 3). RT-qPCR was performed to quantify the relative 
mRNA levels of PanK1 and other p53 metabolic targets. 
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expression of PanK1 during starvation. 
PanK1, specifically the PanK1β isoform, is most highly expressed in the liver in both 
human and mouse. This is consistent with the fact that the liver contains the highest 
concentration of CoA and carries out most CoA-dependent anabolic and catabolic 
reactions. One of the major functions of the liver is to convert stored energy into usable 
fuel sources for different tissues and organs in the body during energy crises. Under 
long-term starvation, the liver undergoes gluconeogenesis from amino acid degradation 
and β-oxidation of fatty acids, both of which are processes that require CoA. With this in 
mind, we wish to examine whether p53 regulates PanK1 expression in the mouse liver 
during prolonged fasting. Since the p53 binding sites of mPank1 is quite conserved 
compared to that of hPANK1 (Figure 2.1), we assumed that the kinetics of mPanK1 
expression under p53 control remains to a similar degree. 
To determine the requirement of p53 on mPanK1β expression in the liver under 
nutrient deprivation, we subjected WT and p53-null mice to either fed or starved 
conditions for 3 days. The liver tissues were subsequently extracted, and the mRNA 
levels of mPanK1β were quantified. Under fed condition, expressions of mPanK1β were 
similar between WT and p53-null mice, suggesting that PanK1 expression is 
p53-independent under adequate energy intake (Figure 2.7B). However, after fasting, 
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mRNA levels of mPanK1β dropped significantly in the p53-null mice, while the WT mice 
was able to maintain the same basal levels of mPanK1β expression (Figure 2.7B). Our 
observation suggests that p53 is required for the maintenance of PanK1 expression in 
the liver during starvation. Interestingly, expression of other p53 metabolic targets did not 
change significantly in the liver with respect to both the presence of p53 and nutrient 
availability, implying that the expressions of these targets are p53-independent in the 
liver and do not respond to fasting (Figure 2.7B). 
 
p53 regulates PanK1 activity and CoA levels in mice after fasting 
Since p53 is required to maintain PanK1 expression during starvation, we wish to 
further investigate the functional consequence of PanK1 expression in the absence or 
presence of p53. First, we tested in vitro PanK activity of cell lysates from H1299 cells 
that were transfected with either p53 or control expression vector. In the presence of 
increasing amount of p53, PanK activity rises proportionally to p53 level (Figure 2.8A). 
We then tested PanK activity in the mouse liver of WT and p53-null mice that were 
subjected to either fed or starved conditions. Under fed condition, WT and p53-null mice 
exhibited similar levels in liver PanK activity, which is consistent with our findings that 








Figure 2.8. p53 regulates PanK1 activity and CoA levels in vivo after starvation. (A) 
H1299 cells were transfected with p53 or PanK1-expressing vectors, and total cell 
extracts were obtained to assay for PanK kinase activity in vitro. (B) WT and p53-/- mice 
were either fed or starved for 3 days, and total liver extracts were obtained and assayed 
for PanK activity (WT fed, n = 3; WT starved, n = 3; p53-/- fed, n = 3; p53-/- starved, n = 3). 
(C) Mice were treated as in B, and levels of liver free CoA were quantified according to 
the Experimental Procedures (WT fed, n = 3; WT starved, n = 3; p53-/- fed, n = 3; p53-/- 




2.8B). Interestingly, p53-null mice exhibited significantly lower liver PanK activity 
compared to WT mice after 3-day starvation (Figure 2.8B), which is parallel to the 
dramatic decrease of PanK1 expression in the liver of starved p53-null mice shown 
before (Figure 2.7B). Furthermore, free CoA levels determined from the liver tissues 
correlate with the levels of PanK activity measured (Figure 2.8C). Together, these data 
suggest that p53 regulates CoA synthesis through maintenance of PanK1 expression 
during starvation. 
 
p53 regulates fat metabolism and gluconeogenesis in the mouse liver 
Since the availability of CoA is crucial for liver function during fasting, we wish to 
examine the consequences of the CoA level discrepancies observed between WT and 
p53-null mice. As previously mentioned, the liver takes up free fatty acids released from 
the fat cells and undergoes β-oxidation to generate ketone bodies, an important energy 
source for the heart and brain during fasting. β-oxidation of fatty acids requires free CoA, 
and we hypothesized that decreased synthesis of free CoA in fasting p53-null mice 
would compromise fatty acid degradation. Indeed, we observed increased concentration 
of long-chain acyl-CoA in the liver of fasting p53-null mice compared to control (Figure 







Figure 2.9. p53 regulates lipid metabolism in the mouse liver. (A) WT and p53-/- mice 
were either fed or starved for 3 days, and the levels of long-chain acyl-CoA in the liver 
were quantified according to the Experimental Procedures (WT fed, n = 3; WT starved, n 
= 3; p53-/- fed, n = 3; p53-/- starved, n = 3). (B) Liver sections obtained from WT and p53-/- 
mice either fed or starved for 3 days were stained with Oil Red O and H&E. The red 
staining from Oil Red O and the clear areas in the H&E staining indicate the presence of 





accumulation of fat droplets in the liver of starved p53-null mice compared to starved WT 
mice via Oil Red O staining (Figure 2.9B). 
In addition to undergoing β-oxidation, the liver also carries out gluconeogenesis 
during fasting to provide energy for glucose-dependent tissues, such as red blood cells. 
There are two processes during gluconeogenesis that are CoA-dependent: 1) 
degradation of amino acid into TCA cycle intermediates; 2) activation of pyruvate 
carboxylase, the enzyme that catalyzes the first step of gluconeogenesis from pyruvate, 
by acetyl-CoA. We predicted that the shrinkage of free CoA pool would lead to 
decreased availability of glucogenic substrates derived from these processes, resulting 
in a slower rate of glucose production. As expected, fasting blood glucose levels were 
significantly lower in the p53-null mice, while no differences were observed for blood 
glucose levels between the two genotypes under normal feeding (Figure 2.10A). 
Furthermore, pyruvate challenge test performed after 16 hrs of fasting revealed a 
marked attenuation of gluconeogenic potential in the p53-null mice, as measured by their 
responding blood glucose levels after injection of sodium pyruvate (Figure 2.10B). 
Taken together, our findings demonstrate that CoA synthesis is p53-dependent under 
nutrient deprivation, and the decrease in liver free CoA levels in the absence of p53 






Figure 2.10. p53 regulates gluconeogenesis in the mouse liver. (A) Blood glucose 
levels were measured in WT and p53-/- mice that were either fed or starved for 2 days 
(WT fed, n = 4; WT starved, n = 4; p53-/- fed, n = 5; p53-/- starved, n = 5). (B) Pyruvate 
challenge test was performed using WT and p53-/- mice that were starved for 16 hours 
(WT mice, n = 5; p53-/- mice, n = 7). Blood glucose levels were measured at different time 





In summary, we have identified PanK1 as a p53 metabolic target and uncovered a 
novel role of p53 in regulating liver CoA abundance during nutrient deprivation through 
PanK1 expression. The involvement of p53 in the physiological response to starvation 
provides clues to the function of p53 in the liver and highlights the significance of p53 




2.2. Chapter 2: Identification of a novel p53 acetylation site at lysine residue K101 
2.2.1. Background and Rationale: 
Recently, roles of p53 have expanded beyond the canonical function of apoptosis 
and cell growth arrest, and now include cellular processes such as metabolism, 
senescence, aging and autophagy. Because of the extraordinary diversity of p53 
functions, many have postulated that mechanisms exist to allow p53 to selectively 
activate downstream targets in specific functional groups, depending on the cellular 
context.  
p53 activity is regulated by a complex network of fine-tuning mechanisms that 
include p53 protein stability, co-activator recruitment, and a diverse array of 
post-translational modifications, including acetylation, ubiquitination, phosphorylation, 
methylation, sumoylation, and neddylation (see Section 1.3). Specifically, acetylation of 
p53 has been established to play a major role in controlling promoter-specific activation 
of downstream targets during stress responses. Our lab has demonstrated that 
acetylation at K120 by Tip60/MOF is important for p53-mediated apoptosis, while 
acetylation at K164 by CBP/p300, along with K120 acetylation, contributes to 
p53-induced cell cycle arrest [93,95]. More recently, the 3KR mouse model that 
expresses acetylation-deficient p53 (K117/161/162R), which mirrors the K120/164R 
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mutations in human p53, demonstrated that while apoptotic and growth arrest functions 
of p53 are lost, p53-dependent metabolic regulation is still intact [107]. These studies 
suggest that there are potentially a large number of p53 targets that can still be 
transcriptionally activated in the absence of K120/164 acetylation (K117/161/162R in 
mouse), including targets such as MDM2, TIGAR and GLS2. Moreover, additional 
modifications may exist that are crucial for the regulation of p53 targets other than 
pro-apoptotic and growth arrest genes. 
 With this in mind, we conducted a screen using mass spectrometry to uncover 
previously unknown modifications. Here, we identified a novel p53 acetylation site at 
lysine K101 within the DNA-binding domain. Lysine residue K101 of p53 is evolutionarily 
conserved and has been found to be mutated in human cancers. In this study, we 
demonstrated that K101 in human p53, as well as the homologous K98 lysine residue in 
mouse p53, can be acetylated by acetyltransferase CBP. Acetylation at this novel site 
does not contribute to p53 stability or DNA-binding capabilities. Ablation of K98 
acetylation in mouse p53 alone does not affect the transcriptional activity of p53. 
However, simultaneous loss of K98 acetylation with the previously characterized 
K117/161/162 acetylations significantly abrogates p53-mediated activation of TIGAR 
and MDM2 genes. 
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2.2.2. Materials and Methods: 
Cell Culture and Transfection. H1299 cells were maintained in DMEM and HCT116 
cells in McCoy’s 5A medium. All media were supplemented with 10% fetal bovine serum. 
Transfections with plasmid DNA were performed using Lipofectamine2000 (Invitrogen) 
according to the manufacturer’s protocol. Tet-on inducible H1299 stable lines were 
generated by transfecting pTRIPZ tetracycline-inducible constructs into H1299 cells, 
followed by puromycin selection (1 μg/mL) for 14 days. Established Tet-on H1299 stable 
lines were maintained in DMEM supplemented with 10% Tet-free FBS (Clonetech). 
 
Plasmids and Antibodies. The plasmids expressing various p53 mutants were derived 
from pCin4-Flag-p53 by mutagenesis using the QuickChange Site-Directed Mutagenesis 
Kit (Stratagene) according to the manufacturer’s instuctions. Mutations at the specific 
sites were confirmed by DNA sequencing. Tet-on inducible mouse p53-expressing 
constructs were generated by subcloning Flag-p53 fragments from pCin4-Flag-p53 into 
pTRIPZ tetracycline-inducible vector (Thermo). TIGAR luciferase construct was 
generated by subcloning a region of the TIGAR promoter containing a p53 binding site 
into pBVLuc luciferase reporter vector (He et al., 1998) using forward primer 5’ – 
GGCTATCGAGGGAAGGAATC – 3’ and reverse primer 5’ – 
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AGGGGGAACCTCAGAAACTG – 3’. Rabbit monoclonal site-specific antibody against 
acetylated K101 p53 was generated in collaboration with Epitomics/Abcam Inc. 
 
Protein Purification and Mass Spectrometry. To purify the acetylated p53 protein for 
mass spectrometric analysis, H1299 cells were co-transfected with CMV-Flag-p53 and 
CMV-CBP-HA, cultured for 16 hours, and then treated with 1 μM TSA + 5 mM 
Nicotinamide for 8 hours. Cells were harvested and lysed in the Flag-lysis buffer (50 mM 
Tris-HCl pH 7.9, 137 mM NaCl, 10 mM NaF, 1 mM EDTA, 1% Triton X-100, 0.2% 
Sarkosyl, 10% glycerol, and fresh proteinase inhibitor cocktail (Sigma)) plus 2 μM TSA 
and 10 mM Nicotinamide. The cell extracts were then immunoprecipitated with the 
anti-Flag monoclonal antibody-conjugated M2 agarose beads (Sigma), and eluted using 
Flag peptide (Sigma). The eluted material was resolved by SDS-PAGE on a 4-20% 
Tris-Glycine gradient gel (Invitrogen), and the p53 bands were excised and subjected to 
mass spectrometric analysis. 
 
Immunoprecipitation and Immunoblot. To immunoprecipitate ectopically expressed 
Flag-p53 proteins, cells were lysed in the Flag-lysis buffer (50 mM Tris-HCl [pH 7.9], 137 
mM NaCl, 10 mM NaF, 1 mM EDTA, 1% Triton X-100, 0.2% sarkosyl, 10% glycerol, and 
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fresh proteinase inhibitor cocktail). Whole cell extracts were immunoprecipitated with the 
anti-Flag monoclonal antibody-conjugated M2 agarose beads (Sigma). The 
immunoprecipitated products were eluted with Flag peptide (Sigma), resolved by 
SDS-PAGE, and detected by antibodies as indicated. 
To detect acetylation of the endogenous p53 proteins at K101, HCT116 cells were lysed 
in Flag lysis buffer. Five milligrams of total cell extracts were incubated with 1 μg of the 
site-specific antibody against acetylated p53 at K101 overnight with rotation. Twenty 
microliters of protein A agarose beads were then added and incubated for 2 hours. 
Beads were washed five times with Flag lysis buffer, and the bound materials were 
eluted in the SDS sample buffer with boiling. The eluted materials were resolved on 
SDS-PAGE gel and detected by the anti-p53 DO-1 antibody (Santa Cruz). 
 
RNA Extraction and RT-qPCR. Total RNA was extracted using TRIzol Reagent (Life 
Technologies) according to the manufacturer’s protocol. cDNA was synthesized from 
total RNA using M-MulV Reverse Transcriptase kit (NEB). PCR analysis was carried out 
using Applied Biosystems 7500 Fast System with the following primers: 5’ – 




Luciferase Activity Assay. Transfection of H1299 cells were performed in 24-well plate 
using 0.2 g TIGAR luciferase reporter constructs, 0.05 g pRL-tk Renilla construct, and 
various amount of vectors expressing wild-type or mutant p53. Luciferase activities were 
measured 24 hours post-transfection using Dual-Luciferase Reporter Assay System 
(Promega). Firefly luciferase activities were normalized with Renilla luciferase activities 
to obtain the relative luciferase activity. 
 
Chromatin Immunoprecipitation (ChIP). The procedure for this assay is essentially 
described in Section 2.1.2 Materials and Methods. The purified DNA were then analyzed 
by PCR within linear amplification range followed by agarose gel electrophoresis. The 
following PCR primers were used: 5’ – CGGCAGGTCTTAGATAGCTT – 3’ and 5’ – 
GGCAGCCGGCATCAAAAACA – 3’ for TIGAR; 5’ – GCACTCTTGTCCCCCAGGCT – 3’ 
and 5’ – GGTCTCCTGTCTCCTACCAT – 3’ for p21. 
 
2.2.3. Results and Discussion: 
p53 is acetylated at the K101 lysine residue by CBP 
To screen for unidentified acetylation of p53, we purified and analyzed ectopically 
expressed p53 protein in H1299 cells in the presence of different histone 
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acetyltransferases by mass spectrometry. To increase the yield of acetylated forms of 
p53, we treated the cells with deacetylases inhibitors trichostatin A (TSA) and 
nicotinamide for 8 hours before isolating the acetylated p53. Our mass spectrometry 
data showed that in the presence of acetyltransferase CBP, p53 is found to be acetylated 
at lysine residue K101, a previously uncharacterized p53 modification (Figure 2.11A and 
2.11B). The K101 lysine residue reside in the DNA-binding domain of p53, and is 
homologous to the K98 lysine residue in mouse p53 (Figure 2.11A). Interestingly, the 
K101 lysine residue appears to be evolutionarily conserved (Figure 2.11B), and has 
been found to be mutated in several different human malignancies. 
To validate the acetylation at K101, we generated a rabbit monoclonal antibody 
specifically against p53 acetylated at lysine K101 (see 2.2.2 Materials and Methods). 
The specificity of the antibody for Western blot was tested by comparing the signal 
detected between wild-type p53 and acetylation-deficient p53 mutant with the K101 
lysine residue replaced by arginine (K101R p53). H1299 p53-null cells were transfected 
with either Flag-tagged wild-type p53 or K101R p53 in the absence or presence of 
acetyltransferase CBP, and the tagged p53 were immunoprecipitated and resolved on 
SDS-PAGE for Western blot analysis. The site-specific AcK101-p53 antibody only 








Figure 2.11. Identification of novel p53 acetylation site at lysine K101. (A) Cartoon 
figure depicting the K101 lysine residue located in the N-terminal end of the DNA-binding 
domain. The K98 lysine residue in the mouse p53 is homologous to the K101 lysine in 
the human p53. (B) Mass spectrometry of purified p53 protein in the presence of CBP 
showed acetylation of p53 at the K101 lysine residue. Cross species alignment of amino 






mutant (Figure 2.12A). Furthermore, K101-acetylated form of p53 was only detected in 
the presence of CBP, which confirmed the mass spectrometry data that CBP indeed 
catalyzes the acetylation of p53 at K101. Similar experiment was performed using 
mouse p53, and the AcK101-p53 antibody also recognized acetylation of mouse p53 at 
K98 in the presence of CBP (Figure 2.12B). Next, we wish to investigate whether p53 
acetylation at K101 occurs endogenously. AcK101-p53 antibody was used to 
immunoprecipitate acetylated form of p53 in HCT116 cells after DNA damage 
(Actinomycin D, Etoposide and Doxorubicin), and the levels of AcK101-p53 were 
detected using anti-p53 DO-1 antibody. As seen in Figures 2.13A and 2.13B, the 
steady-state levels of AcK101-p53 increased as p53 became stabilized after drug 
treatments. These results indicate that K101 of p53 is acetylated both in vitro and in vivo. 
 
Simultaneous mutations at K117/161/162 and K98 impair p53 transcriptional 
activities 
Previous studies have shown that ablation of acetylation at human K120 or mouse 
K117 alone impairs p53-mediated apoptotic induction, while ablation of human K120/164 
or mouse K117/161/162 abrogates the ability of p53 to transactivate both growth arrest 






Figure 2.12. p53 is acetylated by CBP at lysine K101. (A) H1299 cells were 
transfected with vectors expressing either Flag-tagged human wild-type or K101R 
mutant p53 in the presence or absence of CBP. Whole cell lysates were collected and 
Flag-tagged p53 were immunoprecipitated using M2 Flag beads. Whole cell lysate and 
immunoprecipitated products were immunoblotted with site-specific antibody against 
acetylated p53 at K101. (B) Similar experiment to (A) was performed using Flag-tagged 
mouse wild-type or K98R mutant p53, and p53 acetylation at K98 was detected using the 









Figure 2.13. p53 is acetylated at K101 endogenously after DNA damage. (A) 
HCT116 cells were treated with 10 nM Actinomycin D for 0, 8 and 24 hours. 
K101-acetylated fractions of p53 were immunoprecipitated using site-specific antibody 
from whole cell lysates, and the immunoprecipitated products were detected using DO-1 
(p53) antibody. (B) Similar experiment to (A) was performed using 20 μM Etoposide and 





K117/161/162R retains regulation on Mdm2 and certain metabolic targets. In light of 
those findings, we wish to investigate whether ablation of K98 acetylation would further 
impair p53 transcriptional activities. Ectopic expression of K98R p53 in H1299 cells 
showed that the transcriptional activity of this single-mutation p53 was comparable to 
wild-type p53. However, when simultaneously mutating both 3KR (K117/161/162R) and 
K98R, the resulting 4KR98 p53 mutant exhibit significant defect in transactivating Mdm2 
and Tigar expressions (Figure 2.14). 
To characterize the dynamics of downstream target expression in a more 
physiological manner, Tet-on inducible H1299 stable lines conditionally expressing 
wild-type p53 and various p53 mutants were generated. Induction of wild-type p53 and 
3KR p53 expression by doxycycline treatment led to increased expression of Mdm2 and 
Tigar, while induction of the 4KR98 mutant p53 failed to do so (Figure 2.15A and 2.15B). 
These findings demonstrate that ablation of the K98 acetylation alone does not affect 
p53 activity, suggesting functional redundancy through other acetylations (such as 
acetylations at K117/161/162). However, disrupting all four acetylation sites exhibit 
significant defect in p53 transcriptional activity, indicating that in the absence of 
K117/161/162 acetylations, K98 acetylation may be critical for p53-mediated regulation 


















Figure 2.14. Effect of K98 acetylation on the activation of p53 targets in 
overexpression system. H1299 cells were transfected with empty vector and vectors 
expressing wild-type and various KR mutant p53. Expressions of p53 downstream 












Figure 2.15. Effect of K98 acetylation on the activation of p53 targets in Tet-on 
system. (A) H1299 inducible-p53 stable lines expressing wild-type p53 or 3KR/4KR98 
acetylation-deficient p53 were treated with 5 μg/mL doxycycline for 0, 12, 24 and 36 
hours to induce p53 expression. Protein expressions of p53 targets were detected via 
Western blotting using Mdm2, Tigar, Puma and p21 antibodies. (B) Additional set of 
H1299 inducible-p53 stable lines were established expressing wild-type, 3KR or 4KR98 
p53, and downstream p53 targets were analyzed as (A). 
79 
 
To confirm that the defect in activating downstream targets by 4KR98 p53 is 
transcriptional in nature, we quantified the mRNA levels of TIGAR after p53 induction in 
Tet-on inducible stable lines. Indeed, induction of wild-type and 3KR p53 enhanced 
TIGAR mRNA expression, while induction of 4KR98 p53 failed to do so (Figure 2.16A). 
Similarly, co-transfection of TIGAR luciferase reporter construct with vector expressing 
4KR98 p53 mutant in H1299 resulted in diminished reporter activity, compared to 
transfection of vectors expressing wild-type and 3KR mutant (Figure 2.16B). 
 
Acetylation in the DNA-binding domain does not affect p53 stability or DNA 
binding 
One of the functions of p53 acetylation is to increase p53 stability. C-terminal lysine 
residues of p53 have been shown to be ubiquitinated that leads to p53 degradation, and 
that acetylation can occupy these lysine residues to prevent ubiquitination, which thereby, 
increases the stability of p53. Therefore, we wish to examine whether or not human 
K101/mouse K98 and other acetylation sites in the DNA-binding domain affect p53 
stability. We observed that in the presence of Mdm2, wild-type p53 and the 
lysine-to-arginine mutants are degraded to a similar degree (Figure 2.17A). Similar 






Figure 2.16. K98 acetylation affects transcription of TIGAR gene. (A) H1299 
inducible-p53 stable lines expressing wild-type, 3KR or 4KR98 p53 were induced with 5 
μg/mL doxycycline for 0, 12, 24 and 36 hours, and total RNA were extracted. 
Subsequently, reverse transcription was performed on extracted RNA to obtain cDNA, 
and quantitative PCR was performed to measure TIGAR mRNA levels. (B) H1299 cells 
were transfected with TIGAR luciferase construct along with increasing amount of 
plasmids expressing wild-type, 3KR or 4KR98 p53. Cell lysates were collected and 










Figure 2.17. Acetylation in the DNA binding domain does not affect p53 stability. 
H1299 cells were transfected with vectors expressing either (A) human p53, or (B) 
mouse p53 in the presence of increasing amount of Mdm2-expressing plasmid. The 
levels of Mdm2 and p53 proteins were determined via Western blotting using Mdm2 and 







domain does not affect p53 stability (Figure 2.17B). 
Acetylation in the DNA-binding domain also raises the question of whether these 
acetylations alter the affinity of p53 to DNA. To assess the DNA binding capabilities of 
p53 with different acetylation potentials, we performed chromatin-immunoprecipitation 
(ChIP) using wild-type and various acetylation-deficient p53. After doxycycline-induced 
p53 expression in the Tet-on inducible cell lines, wild-type p53, as well as 3KR and 
4KR98 p53, was able to recruit to both p21 and TIGAR promoters (Figure 2.18). 
Collectively, these data suggest that acetylation in the DNA-binding domain does not 
affect p53 stability or DNA binding. Therefore, the mechanism underlying the 
















Figure 2.18. Acetylation-deficient p53 mutants retain the ability to bind p21 and 
TIGAR promoters. ChIP assay was performed on Tet-on inducible H1299 cells 
conditionally expressing wild-type, 3KR, and 4KR98 p53 that were treated with 
doxycycline to induce p53 expression for 8 hours. The immunoprecipitated DNA were 
amplified by PCR using primers that span the p53-binding region on p21 and TIGAR 






2.3. Chapter 3: TNFRSF14 is a novel non-canonical p53 target that contributes to 
tumor suppression 
2.3.1. Background and Rationale: 
 Mechanism of how p53 confer tumor suppression is still unclear. While apoptotic 
and growth arrest functions of p53 can obviously halt or eliminate cells exposed to 
genotoxic stress or oncogenic activation, several evidence indicate that these functions 
of p53 are not essential for suppressing spontaneous tumor formation (see Section 1.4). 
These findings shifted focus towards the importance of non-canonical functions of p53 in 
tumor suppression, with emphasis on p53 metabolic regulation for some time. However, 
to complicate the p53 tumor suppression model even further, many metabolic targets of 
p53 may play dual opposing roles of preventing cancerous metabolic alterations on the 
one hand, and tumor survival on the other (see Section 1.4.2). In light of these collective 
observations, we set forth to identify novel p53 targets that can contribute to 
p53-mediated tumor suppression. Specifically, we wish to uncover targets that are still 
regulated by the 3KR p53 acetylation-deficient mutant, since the 3KR p53 mutant still 
retain tumor suppressive activities (see Section 2.2). 
 From a RNA-seq expression profiling on Tet-on inducible cell line expressing 3KR 
p53, we identified TNFRSF14 (tumor necrosis factor receptor superfamily, member 14) 
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as a novel p53 downstream activation target. TNFRSF14 is a 283-amino acid 
transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) 
family. Also known as HVEM (herpesvirus entry mediator), TNFRSF14 was initially 
discovered as a cell-surface mediator for HSV infection [128]. Unlike many members in 
the TNFR family, this TNFRSF14 does not contain a cytoplasmic death domain. Instead, 
TNFRSF14 is stimulated by its canonical TNF-related cytokine ligand LIGHT 
(TNFSF14/HVEM-L) to activate downstream NF-B pathway during T-cell activation 
[129]. While most functional studies on TNFRSF14 demonstrated its role in 
T-lymphocyte activation and crosstalk between lymphoid cells, evidence also showed 
that this receptor, surprisingly, also play a role in cancer. Cells such as HT-29 and 
MDA-MB-231 that express TNFRSF14 receptor exhibit inhibition of cell growth or 
apoptosis in the presence of LIGHT ligand [130,131]. Hematological malignant cells with 
abundant TNFRSF14 expression can also be sensitized by LIGHT to induce cell death 
[132,133]. Strikingly, several independent cohort studies observed that the TNFRSF14 
gene is frequently mutated in follicular lymphomas and diffuse large B-cell lymphomas 
[134-137].  
 Here, we report that TNFRSF14 is a novel p53 target that can be activated by 3KR 
p53. Interestingly, 4KR98 p53 mutant exhibit significant defect in transactivating the 
86 
 
TNFRSF14 gene. LIGHT ligand expression stimulates cell death in 
TNFRSF14-expressing cells. Moreover, LIGHT expression triggers cell death in Tet-on 
inducible cell line expressing 3KR p53, but not in those expressing 4KR98 p53. 
 
2.3.2. Materials and Methods: 
Cell Culture and Transfection. H1299, Saos2 and MCF7 cells were maintained in 
DMEM and HCT116 and HT29 cells in McCoy’s 5A medium. All media were 
supplemented with 10% fetal bovine serum. Established Tet-on H1299 stable lines were 
maintained in DMEM supplemented with 10% Tet-free FBS (Clonetech). Transfections 
with plasmid DNA were performed using Lipofectamine2000 (Invitrogen) according to the 
manufacturer’s protocol. 
 
Plasmids. Vector expressing full-length LIGHT ligand (TOPO-LIGHT) was generated by 
amplifying the cDNA and performing the TA-cloning into the TOPO vector (Invitrogen). 
Vector expressing secreted soluble LIGHT ligand (CMV9-sLIGHT) was generated by 
amplifying the cDNA and cloning into the Flag-CMV9 vector (Sigma). Tet-on inducible 
TNFRSF14-expressing construct was generated by subcloning TNFRSF14 cDNA 
fragment into pTRIPZ tetracycline-inducible vector (Thermo). All cDNA clones were 
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purchased from Thermo Scientific mammalian ORF collections. The following primers 
were used to amplify the various cDNAs: 5’ – ATGGAGGAGAGTGTCGTACGG – 3’ and 
5’ – TCACACCATGAAAGCCCCG – 3’ for TOPO-LIGHT; 5’ – 
AGTCAAGCTTCAAGAGCGAAGGTCTCACGAG – 3’ and 5’ – 
AGTCGAATTCTCACACCATGAAAGCCCCG – 3’ for CMV9-sLIGHT; and 5’ – 
ATGGAGCCTCCTGGAGACTG – 3’ and 5’ – TCAGTGGTTTGGGCTCCTC – 3’ for 
TNFRSF14.  
 
Chromatin Immunoprecipitation (ChIP). The procedure for this assay is essentially 
described in Section 2.1.2 Materials and Methods. The purified DNA was then analyzed 
by PCR within linear amplification range followed by agarose gel electrophoresis. The 
following PCR primers were used: 5’ – CTGAGAGAGTGGGGTTGGAG – 3’ and 5’ – 
TGGGTCTTGCAAGGAAGAAG – 3’ for TNFRSF14 BS #1; 5’ – 
GCTGAGTTCCTCTGCTGGAG – 3’ and 5’ – CATGGGGAAGAGATCTGTGG – 3’ for 
TNFRSF14 BS #2. 
 
Luciferase Activity Assay. TNFRSF14 promoter-containing fragment was amplified 
from human genomic DNA of H1299 cells and cloned into the pBVLuc luciferase reporter 
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vector containing a minimal promoter using the following primers: forward primer 5’ – 
GCCTGGTGGGTCTATGACTG – 3’ and reverse primer 5’ – 
GTGGACGGAGTGGTGAGTG – 3’. Transfection of H1299 cells were performed in 
24-well plate using 0.2 g TIGAR luciferase reporter constructs, 0.05 g pRL-tk Renilla 
construct, and various amount of vectors expressing wild-type or mutant p53. Luciferase 
activities were measured 24 hours post-transfection using Dual-Luciferase Reporter 
Assay System (Promega). Firefly luciferase activities were normalized with Renilla 
luciferase activities to obtain the relative luciferase activity.  
 
RNA Extraction and RT-qPCR. Total RNA was extracted using TRIzol Reagent (Life 
Technologies) according to the manufacturer’s protocol. cDNA was synthesized from 
total RNA using M-MulV Reverse Transcriptase kit (NEB). PCR analysis was carried out 
using Applied Biosystems 7500 Fast System with the following primers: 5’ – 
GTGTCTGCAGTGCCAAATGT – 3’ and 5’ – CCACACACGGCGTTCTCT – 3’ for 
TNFRSF14; 5’ – AGCGAAGGTCTCACGAGGT – 3’ and 5’ – 





2.3.3. Results and Discussion: 
TNFRSF14 is a novel p53 target 
 RNA-seq expression profile of inducible 3KR-expressing cells revealed that 
TNFRSF14 gene expression is upregulated upon p53 induction. To validate that 
TNFRSF14 gene is indeed a p53 target, we first examined the TNFRSF14 gene 
promoter for p53-binding sites. We found two potential binding sites (BS), with one site 
located ~1.7 kb upstream of the translational start site (TSS), while the other overlaps 
the TSS (Figure 2.19A). Next, we assessed whether p53 can bind to these potential 
binding sites by performing chromatin-immunoprecipitation (ChIP) assay in H1299 cells 
ectopically expressing human and mouse p53. PCR amplification of the 
immunoprecipitated DNA using primers that flank the binding sites showed enrichment of 
p53 binding at both BS #1 and #2, as well as the TIGAR promoter (Figure 2.19B). 
 Next, to evaluate whether p53 can transactivate the TNFRSF14 promoter, we 
generated a luciferase reporter construct containing a 910 bp fragment that overlaps BS 
#2 (Figure 2.19A). Co-transfection of Saos2 p53-null cells with TNFRSF14 reporter 
construct and mouse p53 resulted in an increase in luciferase activity compared to empty 









Figure 2.19. TNFRSF14 is a novel p53 target. (A) Cartoon figure depicts the promoter 
region of the TNFRSF14 gene that contains a p53 consensus binding site (BS) ~1.7 kb 
upstream of the translational start site (TSS) and another overlapping the TSS. A 
luciferase construct was generated by cloning the 910 bp fragment (TNFRSF14 Luc), 
which contains the #2 BS, upstream of a luciferase reporter gene. (B) Chromatin 
immunoprecipitation (ChIP) was performed using H1299 cells transfected with empty 
vector or vectors expressing human or mouse p53 for 24 hours. Short DNA fragments 
spanning the #1 and #2 BS of the TNFRSF14 locus, as well as the BS for the TIGAR 

















Figure 2.20. Transcription of TNFRSF14 is activated in the presence of p53. (A) 
TNFRSF14 luciferase construct (described in Figure 2.18A) was co-transfected with 
either empty vector or p53-expressing vector in Saos2 cells, and cell lysates were 
harvested 24 hours later and assayed for luciferase activity. (B) H1299 cells were 
transfected with either empty vector or p53-expressing vector, and total RNA were 
extracted 24 hours post-transfection. RT-qPCR was performed to determine the mRNA 





the presence of p53, as seen by the elevation of TNFRSF14 mRNA level in H1299 cells 
after transfection of p53 (Figure 2.20B). 
To verify that the transactivation of the TNFRSF14 gene is indeed p53-dependent, 
we compared the induction of TNFRSF14 in the presence or absence of p53. Upon DNA 
damage treatment, HCT116 p53+/+ cells display increased TNFRSF14 expression over 
time, while the absence of p53 in HCT116 p53-/- led to no induction of the gene (Figure 
2.21A). Similarly, TNFRSF14 expression was activated in MCF7 cells after DNA 
damage-induced p53 stabilization. However, MCF7 cells depleted of p53 failed to induce 
TNFRSF14 expression after the same drug treatment (Figure 2.21B). All together, these 
results demonstrate that TNFRSF14 is indeed a bona fide p53 target. 
 
TNFRSF14 regulation is retained by 3KR p53, but not by 4KR98 
 Since p53-mediated upregulation of TNFRSF14 was identified in an expression 
profile of 3KR-expressing inducible cell line, we expect to verify this regulation in an 
overexpression system. Indeed, 3KR p53 was able to enhance TNFRSF14 gene 
expression, albeit at a lower level than wild-type p53. However, with an additional 
acetylation-ablating mutation at K98, the 4KR98 p53 lost transcriptional regulation on 






Figure 2.21. TNFRSF14 gene expression is p53-dependent. (A) HCT116 p53+/+ and 
p53-/- cells were treated with 0.2 g/mL Doxorubicin for the times indicated and total 
RNA were extracted. RT-qPCR was performed to obtain the expression levels of 
TNFRSF14. (B) MCF7 cells were transfected with either non-specific or p53 siRNA, and 
were treated with 0.2 g/mL Doxorubicin for the times indicated at 40 hours 







Figure 2.22. TNFRSF14 expression is abrogated by simultaneous mutation of 3KR 
and K98R. (A) H1299 cells were transfected with constructs expressing wild-type p53 
and various p53 mutants as indicated for 24 hours, and total RNA were extracted for 
quantification of TNFRSF14 mRNA expression via RT-qPCR. (B) Tet-inducible H1299 
cells that conditionally express wild-type, 3KR or 4KR98 p53 were induced with 
doxycycline for the times indicated, and total RNA were extracted to perform RT-qPCR 
for TNFRSF14 expression. 
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doxycycline induction of p53 expression in the Tet-on inducible cell lines resulted in 
upregulation of TNFRSF14 expression by wild-type and 3KR p53, but not by 4KR98 p53 
(Figure 2.22B). To further support these findings, luciferase assay was performed by 
co-transfecting TNFRSF14 reporter construct with wild-type and various mutant p53 in 
Saos2 cells. While wild-type, 3KR and K98R p53 were all able to induce luciferase 
reporter activity, 4KR98 p53 exhibit significant defect in doing so (Figure 2.23). 
Interestingly, similar to previous observation of the DNA binding capabilities of p53 
mutants (see Figure 2.18), 4KR98 p53 still retains the ability to bind TNFRSF14 promoter, 
as determined by ChIP assay (Figure 2.24). These findings show that 3KR p53, but not 
4KR98, can activate TNFRSF14 gene expression, suggesting that the acetylation at K98 
is critical for p53-mediated TNFRSF14 induction in the absence of K117/161/162 
acetylations. 
 
Stimulation of TNFRSF14 by LIGHT ligand leads to cell death 
 Previous studies have shown that activation of TNFRSF14 receptor by LIGHT ligand 
can trigger cell death in many different cell types. While the exact mechanism of how 
TNFRSF14 downstream signaling leads to cell death is unknown, evidence suggests 














Figure 2.23. Defect in transactivating TNFRSF14 by 4KR98 is transcriptional in 
nature. Saos2 cells were co-transfected with TNFRSF14 luciferase construct (described 
in Figure 2.18A) and increasing amount of vectors expressing either wild-type, 3KR, 
K98R or 4KR98 p53. At 24 hours after transfection, cell lysates were collected and 




















Figure 2.24. Ablation of K98 acetylation does not affect DNA binding to TNFRSF14 
promoter. Tet-inducible H1299 stable lines that conditionally express wild-type, 3KR or 
4KR98 p53 were either untreated or induced with doxycycline (5 μg/mL) for 8 hours. 
Cells were then crosslinked with formaldehyde, and DNA-bound p53 were 







before cell death occurs [130,131]. To confirm the TNFRSF14-mediated cell death 
observed in previous studies, we ectopically expressed membranous and soluble LIGHT 
ligand in TNFRSF14-positive cells. Indeed, expression of LIGHT ligand in MCF7 breast 
and HT29 colon adenocarcinomas that express TNFRSF14 led to cell death 48 hours 
after transfection (Figure 2.25). Moreover, we generated inducible 
TNFRSF14-expressing cell line using H1299 lung adenocarcinoma that lacks, or 
maintain very low basal levels of, TNFRSF14 expression to further validate the 
dependency on TNFRSF14 in LIGHT-induced cell death. As expected, 
doxycycline-induction of TNFRSF14 expression in the H1299 stable line resulted in cell 
death in the presence of LIGHT ligand at 72 hours post-transfection, but not in the 
absence of LIGHT or TNFRSF14 expression (Figure 2.26A and 2.26B). 
 In order to determine the type of cell death associated with TNFRSF14, we 
attempted to prevent cell death using inhibitors of various pathways. We transfected 
inducible TNFRSF14-expressing H1299 cells with LIGHT ligand in the presence of 
inhibitors for apoptosis (Z-VAD-FMK), autophagy (3-methyladenine), necroptosis 
(necrostatin-1), or ferroptosis (ferrostatin-1). Surprisingly, treatment of Z-VAD-FMK 
caspase inhibitor, but not others, was able to prevent cell death, suggesting that 

















Figure 2.25. Stimulation of TNFRSF14-positive cells by LIGHT ligand leads to cell 
death. HT29 and MCF7 cells were transfected with either empty vector or vectors 
expressing secreted (CMV9-sLIGHT) or full-length (TOPO-LIGHT) LIGHT ligand. Cell 











Figure 2.26. LIGHT-induced cell death is dependent on TNFRSF14. (A) Inducible 
H1299 cells conditionally expressing TNFRSF14 were transfected with either empty 
vector or vector expressing full-length LIGHT ligand, and were then either left untreated 
or treated with doxycycline (5 μg/mL) for 72 hours. (B) The relative number of live cells 















Figure 2.27. TNFRSF14-mediated cell death can be inhibited by caspase inhibitor. 
TNFRSF14 inducible H1299 cells were transfected with empty vector or vector 
expressing full-length LIGHT ligand. At 4 hours post-transfection, cells were either left 
untreated or treated with doxycycline (5 μg/mL) for 72 hours in the presence of 
Z-VAD-FMK (pan caspase inhibitor), 3-MA (3-methyladenine, autophagy inhibitor), NEC 





signaling (Figure 2.27). All together, these findings indicate that LIGHT ligand can trigger 
TNFRSF14-mediated caspase-dependent cell death with unusually long latency. 
 
LIGHT ligand can trigger TNFRSF14-mediated cell death in 3KR, but not 4KR98, 
cells 
 Since 3KR p53 is defective in promoting apoptosis through the transactivation of 
pro-apoptotic genes, but retains the ability to regulate TNFRSF14, we wish to investigate 
whether induction of 3KR p53 can lead to LIGHT-dependent cell death. To test this, we 
utilized Tet-on inducible p53-expressing H1299 stable lines in conjunction with 
ectopically-expressed LIGHT ligand. As expected, in the absence of p53-mediated 
induction of TNFRSF14, cells expressing LIGHT did not undergo cell death. However, 
with the expression of 3KR p53, LIGHT-expressing cells underwent cell death after 72 
hours of doxycycline-induction and transfection, similar to that observed in Tet-on 
inducible TNFRSF14-expressing H1299 (Figure 2.28A). Interestingly, cells expressing 
4KR98 p53, which lack TNFRSF14 expression, did not undergo cell death upon LIGHT 
expression (Figure 2.28A). Figure 2.28B shows the corresponding expression of p53 
and LIGHT ligand, while Figure 2.28C shows the quantification of live cells in this 








Figure 2.28. LIGHT expression triggers cell death after induction of 3KR p53, but 
not 4KR98. (A) Tet-on inducible H1299 conditionally expressing 3KR or 4KR98 p53 
were transfected with either control vector or vector expressing full-length LIGHT ligand. 
Cells after 4 hours of transfection were left untreated or treated with doxycycline (5 
μg/mL) for 72 hours to induce p53 expression and subsequent cell death. (B) 
Quantification of p53 and LIGHT expression via Western blotting and RT-qPCR, 
respectively. (C) Relative number of live cells was calculated from experiments shown in 






















Our understanding of how p53 functions as a tumor suppressor has evolved 
tremendously since its discovery more than three decades ago. Apoptotic and growth 
arrest functions of p53 have been studied extensively, and have proven to play critical 
roles in maintaining genomic stability through repair or elimination. Later studies 
uncovered diverse array of p53-mediated cellular functions, including metabolism, 
autophagy, senescence, and aging, which contribute significantly to p53 tumor 
suppressive activity. More interestingly, p53 can even go beyond its tumor suppressive 
role and participate in cellular homeostasis and energy balance. 
 
3.1. Identification of PanK1 as a novel p53 metabolic target 
Recent findings have demonstrated the importance of p53 in metabolic regulation. 
In our first study, we have provided evidence that linked p53 function to CoA metabolism 
through a novel p53 metabolic target PanK1, an enzyme that catalyzes the rate-limiting 
step of CoA synthesis. PanK1 was first identified as a potential p53 target from a 
ChIP-on-chip analysis, and subsequent luciferase reporter mutagenesis and gel shift 
assay revealed two p53 binding sites on the 5’-end of PANK1 exon 1, indicating that 
PanK1 is likely a direct p53 target. Expressions of both - and -isoforms of PanK1 are 
shown to be induced by DNA damage in a p53-dependent manner, although the 
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presence of PanK1 expression in p53-null cells suggests concomitant regulation by 
p53-independent pathways as well. 
Many of the previously identified p53 metabolic targets play significant roles in 
modulating the effect of p53-dependent apoptosis or growth arrest. GAMT, while not 
sufficient to trigger cell death, is required to induce the full apoptotic response after p53 
activation [138]. Similarly, it has been shown that TIGAR may partially rescue cells from 
p53-induced apoptosis, while TIGAR mutants exhibit impaired anti-apoptotic activity [39]. 
To our surprise, although PanK1 expression is upregulated under p53 activation in 
response to genotoxic stress, depletion of PanK1 by siRNA targeting did not affect 
p53-mediated cell death after DNA damage. Our findings suggest that p53 regulation on 
PanK1 expression may instead play a role in metabolic settings. 
PanK1 is most highly expressed in the liver, in which it has been shown to carry out 
proper metabolic transformations during fasting that are mediated by adequate CoA 
synthesis; high CoA abundance is required for fatty acid and amino acid degradations 
that generate ketone bodies and glucose as alternative fuel sources under nutrient 
deprivation (Figure 3.1) [125,127]. Indeed, PanK1 knockout mice exhibit reduced fatty 
acid oxidation and gluconeogenesis during starvation due to lower availability of free 










Figure 3.1. A model of p53-mediated PanK1 function through CoA synthesis. 
During starvation, p53 maintains PanK1 expression in the liver and provides adequate 
CoA synthesis to confer energy homeostasis. CoA is required for -oxidation of fatty 
acids to generate acetyl-CoA, which is used as substrate for ketone production. CoA is 
also required for amino acid conversion to TCA-cycle intermediates, which can be 
shuttled into the cytoplasm from the mitochondria to undergo gluconeogenesis. 
Production of both ketone bodies and glucose in the liver during starvation is crucial for 
sustaining energy source for all other organs and tissues. Note that the conversion of 
pyruvate to oxaloacetate is subjected to positive allosteric regulation by acetyl-CoA, 
whose level is dependent on -oxidation and CoA availability. 
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lowered blood glucose levels [127]. Interestingly, gene expressions of all PanK isoforms 
are not elevated during fasting, implying that the existence of other factors, such as 
allosteric regulation, may be important in governing CoA levels [126,127]. Nevertheless, 
in light of the p53  PANK1 axis, we hypothesized that metabolic stress such as 
starvation may at least lead to maintenance of PANK1 gene expression through p53 
activity. To our surprise, while PanK1 expression remained unchanged after glucose 
starvation in HCT116 p53+/+ cells, its p53-/- isogenic counterpart exhibited significant 
decrease in PanK1 protein levels, suggesting that p53 is required for the maintenance of 
PANK1 gene expression under energy deprivation. Consistent with this finding, we 
observed a substantial reduction in the total liver PanK activity as well as the liver free 
CoA levels in fasting p53-null mice. Moreover, the p53-null mice is reminiscent of the 
PanK1-deficient mice in that there are significantly greater accumulation of fatty acid and 
triglyceride after fasting, along with lower fasting blood glucose compared to WT mice, 
demonstrating impairment in both CoA-dependent fatty acid oxidation and 
gluconeogenesis. 
One interesting discovery in our study is that PanK1 expression appears to be 
p53-independent under conditions of excess nutrients. The transition from 
p53-independent to p53-dependent regulation of PanK1 after starvation implies that the 
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unavailability of specific nutrients triggered a switch in the transcriptional machinery 
responsible for PanK1 expression. Previous works have shown that the activity of Sp1, a 
ubiquitously-expressed housekeeping transcription factor that regulates the expression 
of thousands of genes implicated in a diverse array of cellular processes, is dependent 
upon the cellular nutritional and energy status. Fasting, glucose starvation and hypoxia 
can cause degradation of Sp1 or downregulation of the DNA binding activity of Sp1 via 
post-translational modifications such as O-linked glycosylation at serine/threonine 
residues [139-141]. One possibility is that PanK1 expression is regulated by Sp1 during 
normal physiological conditions. However, in the face of energy deprivation, Sp1 activity 
diminishes to conserve nutrients, while p53 is activated in response to metabolic stress 
to maintain the expression of PanK1. Testing this hypothesis would allow us to gain 
better insight on how the metabolic response of p53 fits in the complex dynamics of 
energy homeostasis. 
In this study, we performed ChIP-on-chip assay using an in vitro approach with 
H1299 p53-null cells ectopically expressing human p53. The rationale behind this 
screening method in an artificial system is to be able to identify previously unknown 
metabolic targets of p53. As a result, we were able to establish the p53  PanK1 axis 
and linked p53 function to CoA-dependent metabolism in the liver during starvation. A 
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more specific approach, given that we now know the cell-type localization and specific 
trigger of this p53 function, would be to perform the p53 ChIP assay using liver cells after 
starvation. First, we would expect to see enrichment of p53 binding on the PANK1 
promoter in the liver cells of mice subjected to starvation compared to those that were 
fed. Second, performing a p53 ChIP-on-chip using this in vivo system would potentially 
elucidate other downstream mediators of p53 that may also contribute to p53-dependent 
regulation of energy homeostasis. 
 
3.2. Novel human K101/mouse K98 p53 acetylation contribute to differential 
regulation 
Our identification of a novel p53 metabolic target ultimately led to an increasingly 
puzzling question of how p53 can differentially regulate a vast number of functionally 
diverse target genes in a context-specific manner. This question brought about our 
second study, which sought to uncover novel p53 post-translational modifications that 
may contribute to differential regulation of downstream p53 targets. From previous 
studies in our lab, we have shown that post-translational modifications of p53, 
particularly acetylation of lysine residues, play a crucial role in promoter-specific 
transcriptional activation of p53 targets. The K120 acetylation of p53 is required for 
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transactivation of proapoptotic Puma gene, while K164 and C-terminal acetylations 
contribute to the activation of p21 growth arrest gene, but none is necessary for the 
induction of Mdm2 expression [93,95]. Similar observations were made in the 3KR 
mouse model, in which both apoptotic and growth arrest functions were ablated, while 
regulation on Mdm2 and metabolic targets remained intact [107]. Based on these 
findings, we screened for novel p53 modifications using mass spectrometry and 
identified a new acetylation site at lysine K101 on human p53 (K98 on mouse p53). The 
acetylation, catalyzed by CBP, was confirmed using in-house site-specific antibody 
generated against Ac-K101 p53. Acetylation at K101 in human p53 and K98 in mouse 
p53 lie within the DNA-binding domain, and has been shown to be mutated in human 
cancer. 
We observed that ablation of acetylation at K98 in mouse p53 alone did not affect 
transcriptional activity of p53. Interestingly, when simultaneously disrupting acetylations 
at K117/161/162 and K98, transactivation of targets such as Mdm2 and Tigar, which are 
regulated by 3KR p53, was compromised. Collectively with previous findings, our data 
suggest that the acetylations in the DNA-binding domain of p53 may have redundant 
roles in promoter-specific p53 activation. Activation of pro-apoptotic targets such as 
Puma and Bax require K117 acetylation. On the other hand, p21 growth arrest induction 
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can be achieved by mouse p53 with either K117 or K161/162 acetylation; only ablation of 
acetylation at all three sites will p53-mediated p21 expression be abolished. Moreover, 
activation of targets such as Mdm2 and Tigar by mouse p53 requires only either K98 
acetylation or acetylation(s) at K117/161/162. While which of the three acetylations at 
K117/161/162 could compensate for K98 acetylation in activating Mdm2/Tigar has not 
been tested, it is clear from our data that K98 acetylation is required in the absence of 
K117/161/162 acetylations. These observations indicate that different p53 acetylation or 
combinations of acetylations can be sufficient to activate certain p53 targets. In other 
words, many p53 acetylation sites can be redundant for activating a given target, and 
that the absence of one acetylation can be compensated by another to achieve gene 
expression. 
In light of these findings, we propose an expansion of our working hypothetical 
model detailed in Section 1.5 (Figure 3.2). In the absence of cellular stress, K98 
acetylation in mouse p53 may constitute as minimal modification required for 
p53-mediated expression of genes such as Mdm2 and Tigar. Functionally, expression of 
Mdm2 and Tigar under non-stressed condition is appropriate, as Mdm2 keeps p53 levels 
under tight control, while Tigar activity may contribute to normal cellular energy 











Figure 3.2. An expanded model of differential regulation by p53. Identification of 
human K101/mouse K98 acetylation site further contributed to our working model. The 









apoptotic targets, it is a harmless form of p53 activation that can occur in the absence of 
stress. As cells encounter stress, acetylation of p53 increases depending on the stress 
level, with mild stress triggering growth arrest through K161/162 acetylations, while 
severe stress causing apoptosis via K117 acetylation. 
Even though the acetylation sites in the DNA-binding domain play crucial roles in 
p53 activation and differential regulation, our data suggest that they do not appear to 
significantly affect promoter-specific binding. For example, we observed that wild-type, 
3KR, and 4KR98 p53 can all bind p21 and TIGAR promoters, yet these varieties of p53 
possess drastically different transcriptional activity on p21 and TIGAR gene. One 
possibility is that the acetylations in the DNA-binding domain alters the conformation of 
the p53, and in turn, influences co-activator or transcriptional machinery recruitment 
instead of affecting DNA binding. Co-activators, usually histone acetyltransferases (such 
as CBP/p300, PCAF, GCN5 and Tip60), are recruited by transcription factors to acetylate 
histones and relieve the coiling of chromatin to allow transcription to occur. One study 
showed that acetylation at lysine residues K320/373/381/382 were involved in 
recruitment of co-activators such as CBP and TRRAP that led to histone acetylation of 
the p21 promoter [142]. Furthermore, evidence indicate that DNA binding domain and 
the C terminus of p53 may contain docking sites for several important p53 co-activators 
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such as ASPPs, 53BP1, Tip60/hMOF, hCAS/CSE1L, and HZF, which are all critically 
involved in the induction of different p53 targets [92,93,143-147]. Thus, it is possible that 
different acetylations or combinations of acetylations may present as a form of “code” for 
association with various co-activators, and therefore, allow different p53 target to be 
expressed depending on the co-activator present. Testing whether different co-activators 
are recruited based on the presence of p53 modifications in a promoter-specific manner 
could shed light on the mechanism behind differential regulation by p53. 
 
3.3. TNFRSF14 is a novel non-canonical p53 target that may contribute to 
p53-mediated tumor suppression 
Aside from understanding how p53 can differentially regulate its downstream targets, 
our study on the novel acetylation at K101 also hope to elucidate the mechanism 
underlying p53-mediated tumor suppression. The 3KR mouse model, as well as 
evidence from other studies, demonstrates that apoptotic and growth arrest functions of 
p53 may not be essential for suppressing tumor formation (see Section 1.4). 
Furthermore, the preservation of p53-mediated metabolic function in the 3KR mice 
initially prompted interest in linking cellular metabolism to tumor suppression, but later 
studies revealed that the opposing roles of p53 metabolic genes in both tumor 
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suppression and tumor survival may be difficult to reconcile. Therefore, we decided to 
identify novel mediators of p53 tumor suppressor function in hope of better 
understanding of how p53 prevents cancer. Since 3KR p53 retains the ability to suppress 
spontaneous tumor growth, we profiled gene expression in H1299 cells stably 
transfected with Tet-inducible 3KR p53 expression vector and identified a novel p53 
target, TNFRSF14. 
TNFRSF14, as described in Section 2.3.1, is a transmembrane receptor in the TNF 
receptor family of proteins. The reason for our interest in this particular target was 
two-fold. First, stimulation of the TNFRSF14 receptor can lead to cell death in various 
cancer cells [130-133]. Although the exact mechanism of how TNFRSF14 leads to cell 
death is unclear, it may represent a unique type of tumor suppression that can potentially 
link to immune surveillance (discussed below). Second, TNFRSF14 gene is recently 
found to be highly mutated in follicular lymphomas and diffuse large B-cell lymphomas, 
and may potentially be found to be mutated in other cancers as well if such studies were 
performed [134-137]. Notably, TNFRSF14 is the first p53 target identified that is mutated 
in cancer; even canonical p53 targets such as p21, Puma and Bax are not mutated in 
human cancer in any noticeable frequency.  
Our results show that TNFRSF14 is indeed a bona fide p53 target. Interestingly, 
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regulation on TNFRSF14 expression is retained by 3KR mouse p53, but not by 4KR98 
mutant, which is similar to the expression kinetics observed for Tigar and Mdm2. Parallel 
to what we have observed for other p53 targets, mouse p53 binding on TNFRSF14 
promoter was not significantly affected by the K98 acetylation status, suggesting that 
other mechanism for altering p53 promoter-specific transcriptional activity may be at play 
(as discussed earlier). 
The TNFRSF14 receptor recognizes and binds to LIGHT ligand, which is also a 
transmembrane protein. Stimulation of the TNFRSF14 receptors by LIGHT ligand 
causes cell death in various cancer cell lines, both in our hands and in other published 
works. The TNFRSF14-mediated cell death can be inhibited by pan caspase inhibitor 
(Z-VAD-FMK), suggesting that the apoptotic pathway is likely involved. However, the 
long latency observed before cell death occurs is unusual for apoptotic responses, such 
as ones triggered by DNA damage or hypoxia. TNFRSF14 receptor, unlike many other 
TNF receptors, do not contain cytoplasmic death domain, and therefore, cannot directly 
induce cell death [148]. However, TNFRSF14 activates downstream NF-B pathway 
during T-cell activation, and therefore, it is possible that TNFRSF14-mediated apoptosis 
is carried out by the same pathway. NF-B pathway typically promotes cell proliferation 
and induces anti-apoptotic effects, and aberrant hyperactivity of NF-B is often found in 
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cancer [149,150]. Surprisingly, recent evidence also hints on the possibility of 
pro-apoptotic function mediated by NF-B through the transcription of Fas receptor [151]. 
Coincidentally, a study showed that stimulation of the TNFRSF14 receptor in 
non-Hodgkin’s lymphoma sensitized cancer cells to Fas-induced apoptosis [133]. This 
convoluted hypothetical axis of TNFRSF14  NF-B  Fas could partially explain the 
long latency prior to the initiation of cell death. Other possibilities also exist through 
TNFRSF14-associated TRAF proteins, although many of the downstream pathways 
predominantly promote cell survival (JNK/AP-1/ERK). The TNFRSF14-mediated cell 
death pathway can be further characterized by testing the aforementioned possibilities, 
or through identification of mediators of downstream signal cascade via complex 
purification.  
As mentioned previously, 3KR mice are not prone to spontaneous tumor formation 
in the absence of canonical apoptotic and growth arrest functions. Our findings that link 
p53 to TNFRSF14 function suggest that TNFRSF14 may potentially contribute to 3KR 
p53-mediated tumor suppression. Under in vitro conditions, we observed that 
TNFRSF14 expression induced by 3KR p53 triggered cell death in the presence of 
LIGHT ligand. How this novel mechanism translates into tumor suppression in vivo is of 
great interest for our lab. Based on what is currently known for TNFRSF14 receptor, it is 
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likely that tumor suppression in vivo may involve cross-talks and interactions between 
host cells and the immune system. It would be critical to generate the 4KR98 knock-in 
mice with additional mutation at K98 to determine if there is a loss of tumor suppressive 
function compared to the 3KR mice. It would also be interesting to generate TNFRSF14 
knockout in the 3KR mice to examine whether the TNFRSF14 gene specifically mediates 
tumor suppression in the 3KR p53 background. 
TNFRSF14 receptor is widely expressed in different cell types, including 
lymphocytes and hematopoietic cells (monocytes, dendritic cells, neutrophils, and 
natural-killer cells), as well as parenchymal cells [148]. LIGHT ligand, on the other hand, 
is much more tightly regulated, and its expression is limited to lymphocytes, monocytes 
and immature dendritic cells [152]. In T and B lymphocytes, TNFRSF14 expression is 
high on resting T cells and on naïve and memory B cells, but is downregulated on 
activated T and B cells [153,154]. Interestingly, the expression of LIGHT ligand on 
lymphocytes is reciprocal to that of TNFRSF14. Upon T and B cell activation, LIGHT 
ligand expression increases, while TNFRSF14 expression falls [155]. This expression 
dynamics between the receptor and ligand is presumably to prevent induction of 
TNFRSF14-mediated cell death among the cell population. Moreover, expression of 
LIGHT ligand on activated T and B cells and dendritic cells would hypothetically allow for 
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tumor immune surveillance to take place. 
Further studies are clearly required to elucidate the role in which TNFRSF14 plays 
to confer tumor suppression. Nonetheless, we propose a theoretical model here to serve 
as a guide for future directions (Figure 3.3). Tumor immune surveillance is a critical step 
in checking tumor cell growth in the event that intrinsic tumor suppression mechanisms 
fail [156]. Oftentimes, transformed cells accumulate changes that causes intrinsic 
resistance to apoptosis, ie. overexpression of Bcl-2 or Bcl-XL. In such cases, tumor cells 
will expose tumor-specific antigens on the cell surface via antigen-presenting major 
histocompatibility complex (MHC), which will be recognized by CD8+ killer T cells 
[157,158]. In this scenario, p53-mediated TNFRSF14 expression could serve as a 
co-existing pathway for immune-targeted tumor cell elimination, or even function as a 
failsafe mechanism in the event that tumor cells escape immune surveillance. As 
mentioned earlier, activated lymphocytes express LIGHT ligand on the cell surface, and 
during lymphocyte infiltration into the tumor bulk, these lymphocyte can trigger 
TNFRSF14-mediated cell death through LIGHT ligand binding (in addition to MHC 
recognition and elimination). Moreover, as the process of immune surveillance 
progresses, tumor cells evolve to escape immune detection by disrupting antigen 











Figure 3.3. A hypothetical model for TNFRSF14 function in tumor suppression. 
TNFRSF14 expression could theoretically be maintained by basal p53 activity without 
causing cellular harm (in the absence of TNFRSF14 stimulation). In the event of 
malignant transformation, lymphocytes are recruited to the tumor site to eliminate tumor 
cells presenting tumor antigen (via MHC I and II). Since only activated T and B 
lymphocytes express LIGHT ligand, TNFRSF14 stimulation can serve as an additional 
pathway for tumor killing. Moreover, the TNFRSF14 pathway could also function as a 
failsafe mechanism when tumor cells evolve to escape immune surveillance (ie. 
downregulation of MHC molecules). 
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[157,158]. Under these circumstances, the presence of TNFRSF14 receptor on 
transformed cells could serve as a second line of defense to prevent tumor cells from 
evading immune surveillance. Our hypothesis here links p53 function to tumor immune 
surveillance, and may potentially explain why the 3KR mouse model does not develop 
tumor in the absence of p53-mediated apoptosis and cell cycle arrest. 
It is interesting to note that TNFRSF14 can be activated by 3KR p53, but not by 
4KR98, similar to the pattern observed for Mdm2 and Tigar regulation. Given the 
hierarchical model of p53 activation that we proposed, the p53-mediated expression of 
TNFRSF14 would occur under no or low stress conditions. While stimulation of 
TNFRSF14 leads to cell death via ligand binding, the expression of the receptor alone 
does not cause harm or alter cell fate. Therefore, it would be functionally appropriate if 
TNFRSF14 were regulated by basal p53 activity, as the process of immune surveillance 
would only occur in the event of malignant transformation when LIGHT-positive activated 
lymphocytes are present. 
In summary, our studies have broadened the scope of non-canonical functions of 
p53. We first identified a novel p53 metabolic target, PanK1, which regulates CoA 
synthesis under normal physiological conditions. Even though PanK1 does not 
participate in p53-mediated tumor suppression, our findings shed light on the 
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homeostatic function of p53 and its role beyond cancer biology. We next delved into the 
question of how p53 differentially regulate a wide spectrum of downstream targets, 
especially those that carry out non-canonical p53 functions. Our data suggest that a 
novel p53 acetylation at K101 (K98 in mouse p53), in conjunction with other acetylation 
sites in the core domain, is crucial for promoter-specific activation of downstream targets. 
Furthermore, we characterized yet another novel non-canonical p53 target gene 
(TNFRSF14) that can be regulated by K101 acetylation. Efforts in elucidating the role of 
TNFRSF14 in tumor suppression are still underway, but our current understanding 
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